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The mechanism of vascular formation has been the subject of intensive research for 
many years, but still the mechanisms of vascular stimulation and inhibition remain a 
major topic of investigation. The impact of reactive oxygen species (ROS) and Phos-
phoinositide 3 kinase (PI3K) in vascular differentiating of embryonic stem (ES) cells 
is largely unknown. Here we show that silencing PI3K catalytic subunit p110  and 
NOX1 using short hairpin RNA (shRNA) or inhibition of Rac1 significantly abol-
ished the superoxide (O2-) production stimulated by vascular endothelial growth fac-
tor (VEGF) in mouse ES cells and in  ES cell-derived Flk-1+ vascular progenitor 
cells. Moreover, silencing p110  or inhibition the Rac1 arrested vascular develop-
ment at initial stages of vasculogenesis in embryoid bodies as indicated by PECAM-
1 positive areas and branching points even under VEGF treatment. In sorted Flk-1 
positive ES cells tube-like structure formation on matrigel and cell migration in the 
scratch migration assay were totally impaired in absence of p110 , whereas silencing 
NOX1 in ES cells caused a significant reduction in the PECAM-1 positive area, 
branching points, cell migration and tube length upon VEGF treatment. However, 
vascular differentiation markers were still produced in shRNA VEGF treated NOX1 
knock down ES cells. Interestingly, silencing p110  but not NOX1 significantly in-
hibited the activation of Rac1 and RhoA, which led to abrogation of VEGF-induced 
lamellipodia structure formation. In addition, MAP kinase p44/42 phosphorylation 
was blocked by the PI3K inhibitor wortmannin and the p110  inhibitor com-
pouned15e. In contrast, the NOX1 inhibitor 2-APT did not prevent VEGF-induced 
MAP kinase p44/42 phosphorylation. The efficiency of silencing the p110  catalytic 
subunit of PI3K and NOX1 to inhibit angiogenesis/vasculogenesis were investigated 
for their capacity to inhibit tumor-induced angiogenesis in confrontation cultures 
consisting of embryoid bodies and multicellular DU-145 prostate tumor spheroids. 
Interestingly, we found that silencing p110  can strongly inhibited the vasculariza-
tion of multicellular tumor spheroids in confrontation cultures. These findings pro-
vide direct evidence that the activity of p110  in endothelial cells is essential in vas-
culogenesis/angiogenesis and suggest that p110  and their downstream signalling 
cascade may represent promising therapeutic targets for the treatment of numerous 






Die Vaskulogenese ist seit vielen Jahren Gegenstand intensiver Forschung, dennoch 
sind noch immer die Mechanismen der Gefäßstimulation und Hemmung ein wichti-
ges Thema der Forschung. Insbesondere die Einflüsse reaktiver Sauerstoffspezies 
(ROS) sowie der Phosphoinositide 3 kinase (PI3K) in Bezug auf die Gefäßdifferen-
zierung embryonaler Stammzellen (ES-Zellen), ist noch weitgehend unbekannt. In 
dieser Arbeit wird gezeigt, dass ein mittels spezifischer shRNA durchgeführtes „si-
lencing“ der katalytischen Untereinheit p110  der PI3-Kinase sowie von NOX1 e-
benso wie eine Hemmung von Rac1 zu einer Reduktion der Superoxid Produktion 
bei durch vascular endothelial growth factor (VEGF) stimulierten murinen ES Zellen 
sowie bei ES-Zell abgeleiteten Flk-1+ vaskulären Progenitorzellen führt. 
Darüber hinaus führte ein „silencing“ der katalytischen p110  Untereinheit ebenso 
wie eine Inhibition von Rac1 zu einem Arrest der Gefäßerntwicklung in einem frü-
hen Stadium der Vaskulogense in murinen Embroid Bodies. Dieses ließ sich anhand 
durchgeführter quantitativer PECAM-1 Immunfluoreszenzen sowie anhand der Ana-
lyse von endothelialen Verzweigungspunkten belegen. Der Effekt war selbst insbe-
sondere unter einer zusätzlichen VEGF Stimulation nachweisbar. 
Ergänzend zu diesen Ergebnissen zeigte sich bei der Analyse von aufgereinigten Flk-
1-positiven ES-Zellen, bei denen mittels shRNA Technik die katalytische Unterein-
heit p110  der PI3-Kinase sowie NOX1 nicht translatiert wurden, dass insbesondere 
die dreidimensionale Verzweigung der Endothelzellen auf einer Matrigel-Oberfläche 
sowie die Zellmigration in einem Migrationsassay zu einer signifikanten Verringe-
rung der PECAM-1-positiven Bereiche, der Verzweigungspunkte sowie der Zellmig-
ration führten. Dieser Effekt war insbesondere bei einer zusätzlichen VEGF Behand-
lung nachweisbar.  
Trotz des shRNA silencing von NOX1 ließen sich bei additiver VEGF-Stimulation in 
den untersuchten ES-Zellen auch noch weiterhin typische endotheliale Differenzie-
rungsmarker nachweisen. Interessanterweise führte jedoch ein silencing der katalyti-
schen Untereinheit p110  der PI3-Kinase mittels shRNA, jedoch nicht von NOX1, 
zu einer signifikanten Aktivierung von Rac1 und RhoA, was konsekutiv zu einer 
Inhibition der VEGF-induzierten Bildung von Lamellipodien führte. 
Weiterhin konnte gezeigt werden, dass eine Posphorylierung der MAP Kinase 
p44/42 durch den PI3K Inhibitor Wortmannin und den p110  Inhibitor com-
 
XIV 
pound15e erreicht wurde. Im Gegensatz dazu konnte der NOX1-Inhibitor 2-APT die 
VEGF-induzierte Phosphorylierung der MAP Kinase p44/42 nicht verhindern. Er-
gänzend wurde die Effizienz des shRNA-siliencing der katalytischen Untereinheit 
p110  der PI3K und der NOX1 anhand von Konfrontationskulturen zwischen EBs 
und multizellulären Tumorzellsphäroiden der Prostatakarzinomzellinie DU145, wel-
che eine Tumor induzierte Angiogenese simulieren, evaluiert. 
Interessanterweise fanden wir, dass ein silencing der katalytischen Untereinheit 
p110  zu einer starken Inhibition der Gefäßbildung in den Konfrontationskulturen 
zwischen EBs und multizellulären Tumorsphäroiden führte. Diese Daten belegen, 
dass die katalytische Untereinheit p110  in Endothelzellen für eine reibungslose Va-
sculogenese/Angiogenese ist. Weiterhin legen die erhobenen Daten nahe, das eine 
potentielle pharmakologische Inhibition der katalytischen Untereinheit p110  zu 
einem potentiellen Ansatzpunkt bei der Behandlung zahlreicher Krankheiten, welche 






The vasculature is the first functional organ to develop during embryonic develop-
ment for supply of metabolic substrate (Ribatti 2006). Hemangioblasts (primitive 
angiogenic cells) differentiate into endothelial cells that begin to form rudimentary 
tubes or vessels (Fig. 1.1) and into hematopoietic stem cells that embed in the wall of 
these developing vessels (de Bruijn et al. 2002, Fischer et al. 2006, Risau 1997). The 
mechanism of vascular formation has been the subject of intensive research for many 
years (Folkman 1971, McAuslan and Gole 1980, Patan 2000, Tammela et al. 2008), 
but still the mechanisms of vascular stimulation and inhibition remain a major topic 
of investigation (Muramatsu et al. 2013, Tammela et al. 2008). Numerous publica-
tions have been shown that vascular endothelial growth factor (VEGF) plays a piv-
otal role (Carmeliet et al. 1996, Ferrara et al. 1996) in differentiation and prolifera-
tion of endothelial cells (vasculogenesis) (Pardanaud and Dieterlen-Lievre 1999) and 
blood vessel sprouting and branching (angiogenesis) (Risau 1995) (Fig. 1.1). In addi-
tion, the VEGF receptors, VEGFR1 (fms-related tyrosine kinase-1, Flt-1) and 
VEGFR2 (fetal liver kinase-1, Flk-1/KDR), are also crucial for the development of 
the vascular endothelial cell lineage and for the formation of early capillary net-
works (Fong et al. 1995, Millauer et al. 1993). VEGF has been shown to activate 
several downstream signaling pathways. For example, following VEGF treatment 
Flk-1 (Kroll and Waltenberger 1997), phosphoinositide 3-kinase (PI3K) (Guo et al. 
1995), protein kinase C (PKC) (Xia et al. 1996), Akt (Gerber et al. 1998) and ex-
tracellular-signal-regulated kinase-1/2 (Erk1/2) (Colavitti et al. 2002) were activated. 
However, the cellular signaling pathways and the molecular players involved in the 
vasculogenesis/angiogenesis processes have not yet been fully identified (Adams and 
Alitalo 2007, Welti et al. 2013). By interaction with Flk-1 VEGF regulates endothe-
lial cell development, via activation of class IA PI3K (Bekhite et al. 2011, Bos 1995, 
Gerber et al. 1998). The role of PI3K  in vascular development was demonstrated 
PI3K  knockout mice, which resulted in impaired migration of endothelial cells and 
subsequent loss of angiogenic activity (Bi et al. 1999, Graupera et al. 2008). This 
study provides an avenue for better understanding of the effect of VEGF on blood 
vessels formation to treat many pathological blood vessel conditions (Boheler et al. 





Figure 1.1: Mechanisms of angiogenesis and vasculogenesis  The processes (red labels), 
molecules (green labels) and appearances (black labels) involved in vascular development. 
Red tips in the primary capillary plexus represent sprouts, yellow circles represent splitting 
pillars. Remodelling and maturation is dependent on the tissue and organ context. A, arteri-
ole, V, venule, SMC, smooth muscle cells, PCT, pericytes. (Risau, 1997), used with permis-
sion. 
 
1.1 Phosphoinositide 3-kinase (PI3K)   
Previous publications have shown that PI3K proteins are a key regulatory protein 
that is involved in a wide variety of cellular processes, including cell growth, endo-
thelial proliferation, migration, differentiation, survival and intracellular trafficking. 
(Gerber et al. 1998, Graupera et al. 2008, Jiang et al. 2000). The emerging links be-
tween PI3Ks and many human diseases, including inflammation, cardiovascular dis-




PI3K signaling can be the result of gene mutations, amplification and protein over-
expression (Steelman et al. 2011). The first generation of PI3K inhibitors, in particu-
lar the fungal metabolite wortmannin and the flavone-based compound LY294002 
have been extensively used for more than two decades to analyse PI3K driven path-
ways (Vlahos et al. 1994, Wymann et al. 1996). However, these molecules are poorly 
selective, inhibiting not only the lipid PI3K, but also other members of the PI3K su-
perfamily. For example, kinase profiling has shown that wortmannin and LY294002 
potently inhibit the mammalian target of rapamycin (mTOR) and unrelated enzymes, 
such as casein kinase 2 (CK2), myosin light chain kinase (MLCK) and polo-like ki-
nase (PLK). Furthermore, both agents are known to suffer from problematic pharma-
ceutical properties, particularly in relation to stability and pharmacokinetics (Davies 
et al. 2000, Knight et al. 2004, Liu et al. 2005). Consequently, some of the pheno-
types that were originally attributed to class I PI3K, using these inhibitors, could also 
be due to the inhibition of other related pathways. Concomitantly, some of the phe-
notypes observed in gene-modified mice that lack the entire PI3K protein (gene dele-
tion, knockout mice), as opposed to mice that only lack PI3K enzyme activity (site-
directed kinase-inactive mutant, knock-in mice), could also be caused by the loss of 
protein functions that are independent of class I PI3K enzymatic activity (Clayton et 
al. 2002, Okkenhaug et al. 2002). It is therefore advisable to combine genetic and 
pharmacological strategies for the analysis of PI3K-mediated signalling cascades.  
 
1.1.1 PI3K structure 
PI3Ks are evolutionary conserved from yeast to high mammals and are classified 
based on their lipid specificity, molecular structure, cellular regulation and in vivo 
substrate specificities into class I, II and III PI3Ks (Vanhaesebroeck et al. 1997). The 
most important enzymes related to vascular differentiation are class I enzymes, 
which are further divided into class IA (PI3K , , ) and class IB (PI3K ) enzymes 
(Marone et al. 2008, Morello et al. 2009). All four class I PI3Ks are heterodimers 
composed of a catalytic subunit with a molecular weight of 110 kDa and a tightly 
associated regulatory subunit that controls activation and subcellular localization 
(Stephens et al. 1991, Whitman et al. 1988). All catalytic subunits of the depicted 
kinases share a core catalytic domain (PI3Kc), which contains the ATP-binding site 
(Fig. 1.2). At their N-terminus, the catalytic domains of PI3K class I have a regula-




binds p101 and p84/87PIKAP proteins), followed by a Ras-binding domain (RasB), a 
C2 domain (protein kinase C homology domain 2) and a PI3K accessory (helical) 
domain (PI3Ka). The 110 kDa catalytic subunit of PI3K , the only class IB PI3K 
isoform described so far, associates with one of two regulatory subunits, p101 and 
p84 (also known as p87PIKAP), that are distinct from any of the p85 subunits. PI3K  
contains interaction sites for  subunits of trimeric G proteins in the pRegB and the 
PI3Kc domains (Fig. 1.2). The regulatory subunits of class IA PI3Ks contain a P 
(proline-rich region), two SH2 (Src-homology 2) domains, as well as an iSH2 region, 
which interacts with the catalytic subunit. p85  and p85  have at the N-terminus an 
additional SH3 (Src-homology 3) and BH (BCR homology) domain. The structure of 
p101 and p84/87PIKAP is not well explored (Fig. 1.2). The N-terminus is required for 
association with PI3K , and G  interaction is mediated by the C-terminal part of 
these adaptors (Marone et al. 2008, Stephens et al. 1994). 
 
 
Figure 1.2: Domain structure of PI3K class I. From Marone et al (2008), used with per-
mission. 
 
1.1.2 PI3K activation 
Class IA PI3Ks are mainly present in cytoplasm without stimulation, where p85 sub-
unit forms dimer with p110 and prevents it from degradation. Activation of PI3K by 
ligands involves its translocation to the plasma membrane so as to gain access to 




downstream of growth factors, cytokine receptors and their substrates, whereas 
PI3K  activation is triggered downstream of G protein-coupled receptors (GPCRs). 
Binding of growth factors to their cognate receptor leads to receptor dimerisation and 
auto-phosphorylation of multiple tyrosines. This act as docking sites for the SH2 
domains present in the PI3K regulatory subunits p85, p55, and p50 (Fig. 1.3). This 
translocates the catalytic PI3K subunit to the plasma membrane to initiate the phos-
phorylation of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) giving rise to 
the second messenger phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) 
(Koyasu 2003, Marone et al. 2008). PtdIns(3,4,5)P3 then recruits proteins with a 
pleckstrin homology (PH) domain and amplifies the growth factor signaling cascade 
(Fig. 1.3). In the case of PI3K , binding of chemokines to GPCRs induces the disso-
ciation of heterotrimeric G-proteins. Free G  subunits interact with PI3K  and the 
adaptor proteins p101 and p84/87, usually triggering transient, high amplitude sig-
nals of PtdIns(3,4,5)P3 (Wymann et al. 2003).  
 
 
Figure 1.3: Simplified activation scheme of class I PI3Ks. (Marone et al., 2008), used 
with permission. 
 
1.1.3 PI3K-Akt signaling pathway 
The most important link between PI3K and its downstream targets is Akt also known 
as protein kinase B (PKB) (Sui et al. 2008). The PI3K- Akt pathway is highly con-
served, and its activation is tightly controlled via PtdIns(3,4,5)P3. PI3K-Akt signaling 




lial cell stimuli including angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2) (Brindle et 
al. 2006, Papapetropoulos et al. 2000), insulin-like growth factor-I (IGF-I) (Michell 
et al. 1999), sphingosine-1-phosphate (S1P) (Igarashi and Michel 2001, Morales-
Ruiz et al. 2001) and hepatocyte growth factor (HGF) (Nakagami et al. 2001), indi-
cating the pivotal role of this signaling pathway in controlling endothelial cell sur-
vival, adhesion and migration, which are important processes in angiogenesis. 
 
1.2 The reactive oxygen species 
Increased oxidative stress plays a central role in the pathogenesis of vascular disease 
(Heistad 2006, Madamanchi et al. 2005, Violi et al. 2005). However, moderate levels 
of reactive oxygen species (ROS), such as superoxide anions (O2-) and hydrogen 
peroxide (H2O2), produced in response to the activation of various cell surface recep-
tors and serve as intracellular signals to mediate various biological responses such as 
cell migration, proliferation, gene expression and angiogenesis (Caliceti et al. 2014, 
Oshikawa et al. 2012, Ushio-Fukai and Urao 2009). Furthermore, many studies have 
revealed that a major source of ROS is generated from nicotinamide adenine dinu-
cleotide phosphate (NADPH) oxidase (NOX), which play an important role in Flk-1 
signaling and angiogenic responses in endothelial cells (Ushio-Fukai 2007, Ushio-
Fukai and Urao 2009). Although the role of ROS in angiogenesis has been reported 
(Maulik 2002, Sauer et al. 2005, Sauer and Wartenberg 2005), the upstream signal-
ing events stimulating ROS production by VEGF-PI3Ks are still not well character-
ized (Chatterjee et al. 2012, Chen et al. 2006, Kennedy and DeLeo 2008).  
NADPH oxidases are comprised of membrane proteins (i.e. the catalytic flavin–heme 
protein), NOX, of which five isoforms exist (NOX1–5), and the non-catalytic 22 kDa 
binding protein, p22phox. Catalytic NOX subunits include an N-terminal domain 
composed of 6 transmembrane helices, numbered I though VI. Four histidine resi-
dues in helices III and V coordinate 2 heme (Fig. 1.4). The iron in haems is capable 
of undergoing reduction and re-oxidation, thereby functioning as an electron carrier. 
The two haems together provide a channel for electrons to pass across the membrane. 
A cytosolic C-terminal dehydrogenase domain includes an flavin adenine dinucleo-
tide (FAD) cofactor and NADPH substrate binding site. Both NOX1 and NOX2 form 
a complex with p22phox, which includes 2 transmembrane domains and a C-terminal 
proline-rich region (PRR) (Lassegue and Clempus 2003, Lassegue et al. 2012). Other 




Noxo1), an activator (p67phox or Noxa1) and p40phox (only with p67phox) (Lassegue et 
al. 2012, Opitz et al. 2007). On activation, electrons are transferred from NADPH to 
flavin adenine dinucleotide (FAD)  and across the membrane, via heme irons, to mo-
lecular oxygen, thus producing superoxide anion (O2-), which can be dismutated into 
hydrogen peroxide (H2O2) as indicated in Figure 1.4 (Lassegue et al. 2012). How-
ever, NOX4 and NOX5 may be independent of cytosolic subunits and constitutively 
active (Bedard and Krause 2007, Lambeth et al. 2007, Opitz et al. 2007). NOX4 also 
forms a complex with p22phox. Whereas NOX5 is composed of a catalytic subunit 
plus an amino-terminal calcium-binding domain with 4 EF-hands (Bedard and 
Krause 2007, Lassegue et al. 2012) (Fig. 1.4).  
 
 
Figure 1.4: Subunits composition and activation of NOX enzymes. Both NOX1 and 
NOX2 (blue) form a complex with p22phox (green). A cytosolic complex, is composed of an 
organizer (Noxo1 or p47phox), an activator (Noxa1 or p67phox) and p40phox (only with p67phox). 
The organizer, stimulated by phosphorylation (red dots) in the case of p47phox, binds the pro-
line-rich region of p22phox and membrane lipids. Likewise, p40phox binds lipids in endosomal 
membranes. Rac, activated by GTP (brown dot), binds membrane, NOX and NOX activators 
which trigger FAD reduction. Nox4 (blue) also forms a complex with p22phox. Its activity, 
constitutive in the absence of cytosolic subunits, can be increased by binding of polymerase 
delta interacting protein 2 (Poldip2) to the cytosolic C-terminal of p22phox. NOX5 is com-
posed of a catalytic subunit similar to the other oxidases (blue), plus an amino-terminal cal-
cium-binding domain (red) with 4 EF-hands. Binding of cytosolic calcium to the EF hands 
triggers NOX5 activation. (Lassègue et al., 2012), used with permission. 
 
 A previous study has demonstrated that ras-related C3 botulinum toxin substrate 1 
(Rac1) activity corresponds with angiogenesis in hepatocellular carcinoma (Lee et al. 
2006). Moreover, it has been found that PI3K regulates the cell migration through 
activation the Rac1 (Williams et al. 2000, Xu et al. 2012). Also, Rac1 has been found 
to bind to NOX1 and NOX2 and activate NADPH oxidase (Lambeth 2007). Other 
studies have shown that Rac1 is involved in the control of angiogenesis by inducing 




worthwhile to explore whether PI3K and Rac1 signaling pathways are involved in 
VEGF-induced ROS production in vasculogenesis/angiogenesis of ES cells. 
1.3 Embryonic stem cells 
The first murine embryonic stem (ES) cell lines were successfully derived directly 
from inner cell mass (ICM) of pre-implantation embryos at the blastocyst stage in 
1981 (Evans and Kaufman 1981). The abilities of ES cells to self-renew indefinitely 
and to differentiate in all the three germ layers make these ES cells very attractive 
tool to investigate molecular mechanisms and genes involved in mammalian devel-
opment (Rathjen et al. 1998). ES cells can be maintained in their pluripotent state if 
cultured in the presence of leukemia inhibitory factor (LIF) or cultured on feeder 
layers, which inhibit their differentiation. When LIF is removed, ES cells spontane-
ously differentiate in vitro and form embryo-like aggregates, called the embryoid 
bodies (Fig. 1.5), which can give rise to any cell type in the body including hemato-
poietic cells, neuronal cells, cardiomyocytes and muscle cells, epithelial cells, and 




Fig. 1.5: In vitro differentiation of ES cells. ES cells isolated from inner cell mass (ICM) 
of pre-implantation embryos at the blastocyst stage. Undifferentiated mouse ES cells (A) 
develop in vitro via three-dimensional aggregates (embryoid body, B) into differentiated cell 
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types of all three primary germ layers. Shown are differentiated cell types labeled by tissue-
specific antibodies (in parentheses). C: cardiomyocytes (titin Z-band epitope). (D), skeletal 
muscle (titin Z-band epitope). (E), smooth muscle (smooth muscle -actin). (F), neuronal 
( III tubulin). (G), glial (glial fibrillary acidic protein, GFAP). (H), epithelial cells (cy-
tokeratin 8). (I), pancreatic endocrine cells [insulin (red), C-peptide (green), insulin and C-
peptide colabeling (yellow)]. (K) and (L), hepatocytes (K, albumin, L, 1-antitrypsin). (mod-
ified from Wobus and Boheler, 2005). 
 
1.4 Differentiation of pluripotent ES cells into endothelial cell 
The abilities of ES cells to differentiate into endothelial cell and vascular structure 
formation provide a powerful in vitro model system to study the molecular mecha-
nisms of earliest stages of vascular formation (Vittet et al. 1996). Moreover, the ex-
pression of various endothelial cell markers in the ES cells derived embryoid bodies 
was found to follow the sequence of events occurring in vivo (Kabrun et al. 1997, 
Redick and Bautch 1999). Interestingly, vascular progenitor cells in 4-day-old em-
bryoid bodies express the Flk-1 one of the early marker for endothelial lineage 
(Keller 2005). Furthermore, the isolated Flk-1 positive cells from the ES cells were 
able to differentiate in vitro and also in vivo into vascular endothelial cells 
(Yamashita et al. 2000). We previously established purification system for Flk1+ 
cells from ES cells and showed that Flk1+ cells give rise to endothelial cells in vitro 
(Bekhite et al., 2011). Therefore it is possible to track the transition from early dif-
ferentiation to mature vascular cells, distinguishing them from other cell lineages. 
The ES model system has the advantage to be devoid of interference with host re-
sponses. Moreover, it may constitute an alternative to animal experimentation, which 
suffers from ethical constraints. Moreover, the ES system allows the study of both 
vasculogenesis and angiogenesis, which is a unique property conferring superiority 
to all other in vitro angiogenesis models. In addition, the differentiation of geneti-
cally modified ES cells analyses are also excellent alternatives and substitutes to in 
vivo studies to analyze the consequences of vascular development (Wobus and 
Boheler 2005). Moreover, this model responding to both positive and negative modu-
lators of angiogenesis can be exploited for the identification of novel signaling mole-
cules (Feraud et al. 2001).Due to increasing the number of new antiangiogenic 
agents, each of them representing promising tools in therapy, this model can be use-






1.5 Tumors and antiangiogenic therapies 
More than a century ago, early pioneering researchers observed that dense vascular 
networks often accompanied human tumors (Ide et al. 1939). In 1971, Judah Folk-
man, who became known as the “father of tumor angiogenesis,” first emphasized the 
importance of tumor vascularity for tumor growth (Folkman 1971). This observation 
led to the development of antiangiogenic therapy by Folkman and colleagues 
(Folkman 1971, Folkman et al. 1971), which is based on the assumption that inhibi-
tion of tumor-induced angiogenesis would deprive the growing tumor of nutrients 
and oxygen supplied by the host circulation and, consequently, would retard or even 
abolish tumor growth. In a similar manner as in embryogenesis, most tumor masses 
grow avascular, until an equilibrium between proliferation and apoptosis is reached, 
and thus can persist in this dormant encapsulated state (Leite de Oliveira et al. 2011). 
The gradient in oxygen, pH, nutrients and the absence of sufficient detoxicfication 
then results in growth arrest (Awwad et al. 1986). Many tumors produce growth fac-
tors that stimulate angiogenesis, other tumors somehow induce surrounding normal 
cells to synthesize and secrete such factors as presented in figure 1.6. The resulting 
new blood vessels “feed” growing tumors with oxygen and nutrients, allowing the 
cancer cells to invade nearby tissue, to move throughout the body and to form new 
colonies of cancer cells, called metastases (Ferrara and Kerbel 2005). The "angio-
genic switch" that initiates this process depends on a net balance of positive and 
negative angiogenic factors secreted by tumor  (Keyhani et al. 2001). The VEGF 
family of ligands and receptors are potent inducers of angiogenesis. In most circum-
stances, the increased production of VEGF begins when tumors grow into certain 
size and tumor cells within the tissue undergo hypoxia (Roskoski 2007). The use of 
VEGF blockers to prevent this process is the most established of the anti-angiogenic 
modalities (Ferrara and Kerbel 2005, Kim et al. 1993). However, several studies 
have shown that VEGF blockade damages not only tumor vessels but also healthy 
vessels and results in severe problems such as hemorrhagic and thrombotic events 





Figure 1.6: Tumor produce growth factors that stimulate angiogenesis for delivery of 
oxygen and nutrients required for their growth and metastasis. (a), tumour cells produce 
VEGF-A and other angiogenic factors such as basic fibroblast growth factor (bFGF), angio-
poietins, interleukin-8, placental growth factor (PlGF) and VEGF-C. These stimulate resi-
dent endothelial cells to proliferate and migrate. (b), an additional source of angiogenic fac-
tors is the stroma. This is a heterogeneous compartment, comprising fibroblastic, inflamma-
tory and immune cells. Recent studies indicate that tumour-associated fibroblasts produce 
chemokines such as stromal cell-derived factor-1 (SDF-1), which may recruit bone-marrow-
derived angiogenic cells (BMC). Tumour cells may also release stromal cell-recruitment 
factors, such as platelet-derived growth factor-A (PDGF-A), PDGF-C or transforming 
growth factor (TGF). A well-established function of tumour-associated fibroblasts is the 
production of growth/survival factor for tumour cells such as epidermal growth factor recep-
tor (EGFR) ligands, hepatocyte growth factor (HGF) and heregulin. (c), endothelial cells 
produce PDGF-B, which promotes recruitment of pericytes in the microvasculature after 
activation of platelet-derived growth factor receptors (PDGFR). HGF, hepatocyte growth 
factor. (Ferrara and Kerbel, 2005), used with permission. 
 
1.5.1 Confrontation culture of ES cells with multicellular tumor spheroids  
Multicellular tumor spheroids are three-dimensional cell systems for avascular mi-
crometastases or avascular microregions of solid tumors (Mueller-Klieser 1997). 
Multicellular aggregates are more useful than two-dimensional monolayer cultures 




structure is important for cell-to-cell and cell-to-matrix interactions. These spheroids 
have been applied in various studies, including study tumor-induced angiogenesis, 
i.e., the invasion of endothelial host-derived cells into a tumor tissue (Wartenberg et 
al. 2001). Using confrontation culture consists of embryoied bodies and multicellular 
tumor spheroids from human prostate carcinoma cell line (DU-145), tumor-induced 
angiogenesis were studied in NOX1 isoform and PI3K  knockdown embryoid bodies 
derived from ES cells. 
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2. AIM OF THE STUDY   
The aim of the study is to investigate the role of class IA PI3K -NADPH oxidases 
signaling pathways and their downstream effectors that mediate VEGF-induced an-
giogenesis/vasculogenesis of mouse embryonic stem (ES) cells. Thus the aims were:  
1. To determine the expression pattern of class IA PI3K catalytic subunits 
p110 , Flk-1 and the vascular differentiation indicted by CD31 (PECAM-
1) as well as intracellular ROS production in the embryoid bodies derived 
from the ES cells. 
2. To determine whether ROS is necessary for VEGF-PI3K signaling regu-
lated vasculogenesis/angiogenesis.  
3. To determine whether the ROS production from NADPH oxidases is de-
pend on PI3K activation. 
4. To study the role of PI3K -NADPH oxidases for vasculogene-
sis/angiogenesis and cell migration using ES cells stably producing 
shRNA targeting PI3K  or NADPH oxidases. 
5. To assessment the efficiency of inhibition the NOX isoform and PI3K  
on tumor-induced angiogenesis using the confrontation cultures consist-
ing of embryoid bodies and multicellular DU-145 prostate tumor sphe-
roids. 
This study may provide an avenue for better understanding of the effect of VEGF on 
blood vessels formation to treat many pathological blood vessel conditions. 
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Agar gel electrophoresis  Biometra GmbH, Göttingen, Germany 
AMAXA Nucleofector Loanza Cologne GmbH, Germany 
Analytical balance BP 221S Sartorius AG, Göttingen, Germany 
ApoTome Carl Zeiss AG, Jena, Germany 
Autoclave MELAG oHG, Berlin, Germany 
Cellspin stirrer system Integra Biosciences GmbH, Fernwald, Germany 
Cell scrapers Greiner Bio-One GmbH, Frickenhausen, Germany 
Centrifuge Hettich GmbH & Co. KG, Tuttlingen, Germany 
Clean bench HERAsafe Heraeus Instruments GmbH Hanau, Germany 
CO2-incubator HERAsafe Heraeus Instruments GmbH Hanau, Germany 
Counting cell chamber Paul Marienfeld GmbH & Co. KG, Germany 
FACSCalibur Becton Dickinson GmbH, Heidelberg, Germany 
Hot plate  Labotect, Rosdorf, Germany 
Laboratory centrifuge  Eppendorf AG, Hamburg, Germany 
LAS-3000 imager Fujifilm, Tokyo, Japan 
LSM 510 Carl Zeiss AG, Jena, Germany 
Light-optical microscope 
TELAVAL 31 
Carl Zeiss AG, Jena, Germany 
MACS Separator Miltenyi GmbH, Bergisch Gladbach, Germany 
Magnetic plate stirrer IKA-Werke GmbH & Co. KG, Staufen, Germany 
Mastercycler gradient Eppendorf AG, Hamburg, Germany 
Microplate reader infinite 
m200 
Tecan Group, Switzerland 
Mini-PROTEAN 3 Multi-
Casting Chamber 
BioRad GmbH, Dreieich, Germany 
Mini-PROTEAN 3 glass 
plates 
BioRad GmbH, Dreieich, Germany 
Mini-PROTEAN 3 spacer 
plates 
BioRad GmbH, Dreieich, Germany 
Nanodrop  Peqlab Biotechnologie GmbH, Erlangen, Germany 
pH-meter inoLAB WTW GmbH, Weilheim, Germany 
Photometer Eppendorf AG, Hamburg, Germany 
Pipettor Integra Biosciences GmbH, Fernwald, Germany 
PowerPacTM 300 Power 
Supply 
BioRad GmbH, Dreieich, Germany 
Shaker TH15 Edmund Bühler GmbH, Germany 
Spinner flask cellspin  Integra Biosciences GmbH, Fernwald, Germany 
Syngene G:Box  VWR International GmbH, Darmstadt, Germany 
MATERIAL AND METHODS 
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Thermal cycler UNO II Biometria GmbH, Göttingen, Germany 
Water bath Grant SUB36 VWR International GmbH, Darmstadt, Germany 




AxioVision Carl Zeiss AG, Jena, Germany 
Image Reader LAS-3000 Fujifilm, Tokyo, Japan 
CellQuest Pro Becton Dickinson GmbH, Heidelberg 
EndNote Thomson Reuters, San Francisco, USA 
GraphPad Instat 3 GraphPad Software, San Diego, USA 
LSM Image Examiner Software Carl Zeiss AG, Jena, Germany 
LSM 510 software Carl Zeiss AG, Jena, Germany 
SigmaPlot 12.0 Systat Software, München, Germany 
Syngene GeneTools image 
analysis program 
Syngene, Maryland, USA 
 
3.1.3 Chemicals and reagents 
Name Producer 
Acetone Carl Roth GmbH & Co.KG, Karlsruhe Germany 
Acrylamide-bisacrylamide 
(40%) 
Merck KGaA, Darmstadt, Germany 
Agarose SERVA GmbH,  Heidelberg , Germany 
APS Merck KGaA, Darmstadt, Germany 
Aprotinin Merck KGaA, Darmstadt, Germany 
Bromophenol blue Sigma-Aldrich GmbH, Taufkirchen, Germany 
BSA Sigma-Aldrich GmbH, Taufkirchen, Germany 
Calcium chloride Sigma-Aldrich GmbH, Taufkirchen, Germany 
Carbamide, urea ( 99.5%) Carl Roth GmbH & Co.KG, Karlsruhe Germany 
Celltracker CMFDA Invitrogen GmbH, Karlsruhe, Germany 
Collagenase type II PAA GmbH, Coelbe, Germany 
DHE Invitrogen GmbH, Karlsruhe, Germany 
DMSO Sigma-Aldrich GmbH, Taufkirchen, Germany 
DTT Invitrogen GmbH, Karlsruhe,  Germany 
Dulbecco’s PBS PAA GmbH, Coelbe, Germany 
ECLTM Western blotting detec-
tion reagents 
Amersham GmbH, Freiburg, Germany 
Ethanol ( 99.8%) Merck KGaA, Darmstadt, Germany 
EDTA Sigma-Aldrich GmbH, Taufkirchen, Germany 
Gelatine Sigma-Aldrich GmbH, Taufkirchen, Germany 
Glucose Sigma-Aldrich GmbH, Taufkirchen, Germany 
Glycine Sigma-Aldrich GmbH, Taufkirchen, Germany 
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HEPES  Sigma-Aldrich GmbH, Taufkirchen, Germany 
H2DCF-DA Invitrogen GmbH, Karlsruhe, Germany 
LB-Agar, powder (Lennox L 
agar) 
Invitrogen GmbH, Karlsruhe, Germany 
Leupeptin hydrochloride  Sigma-Aldrich GmbH, Taufkirchen, Germany 
Magnesium chloride Sigma-Aldrich GmbH, Taufkirchen, Germany 
Magnesium sulphate Sigma-Aldrich GmbH, Taufkirchen, Germany 
Methanol (>99%) Carl Roth GmbH & Co.KG, Karlsruhe Germany 
Milk powder, blotting grade Carl Roth GmbH & Co.KG, Karlsruhe Germany 
Pepstatin A, 100,000 units/mg Sigma-Aldrich GmbH, Taufkirchen, Germany 
PFA Carl Roth GmbH & Co.KG, Karlsruhe Germany 
Phenylmethylsulfonyl fluoride  Sigma-Aldrich GmbH, Taufkirchen, Germany 
Phosphatase inhibitor Cocktail 3 Sigma-Aldrich GmbH, Taufkirchen, Germany 
Potassium chloride Carl Roth GmbH & Co.KG, Karlsruhe Germany 
Sigmacote Sigma-Aldrich GmbH, Taufkirchen, Germany 
Sodium chloride Carl Roth GmbH & Co.KG, Karlsruhe Germany 
SDS( 99.0% ) Sigma-Aldrich GmbH, Taufkirchen, Germany 
Sodium hydrogen phosphate Sigma-Aldrich GmbH, Taufkirchen, Germany 
Sodium hydroxide Carl Roth GmbH & Co.KG, Karlsruhe Germany 
Sodium pyruvate Biochrom AG, Berlin, Germany 
Sodium vanadate ( 90%)  Sigma-Aldrich GmbH, Taufkirchen, Germany 
Taurine  Sigma-Aldrich GmbH, Taufkirchen, Germany 
TEMED Merck KGaA, Darmstadt, Germany 
Tris base ( 99.8%) Sigma-Aldrich GmbH, Taufkirchen, Germany 
Triton® X-100 Sigma-Aldrich GmbH, Taufkirchen, Germany 
Tween 20 Carl Roth GmbH & Co.KG, Karlsruhe Germany 
 
3.1.4 Antibodies 
3.1.4.1 Primary antibodies 
Antigen Origin Dilution Producer 
Polyclonal GAPDH Rabbit 1:1000 Abcam 
Phosphor-RhoA (Ser188)   Rabbit 1:1000 Abcam 
Polyclonal RhoA Rabbit 1:1000 Cell Signaling Technology 
Rac1/2/3 Rabbit 1:1000 Cell Signaling Technology 
Phosphor-Rac1(Ser71) Rabbit 1:1000 Cell Signaling Technology 
Phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) 
Rabbit 1:1000 Cell Signaling Technology 
Phospho-p38 MAPK 
(Thr180 /Tyr182) 
Rabbit 1:1000 Cell Signaling Technology 
Phospho-SAPK/JNK 
(Thr183 /Tyr185) 
Rabbit 1:1000 Cell Signaling Technology 
Phospho-Akt (Ser473) Rabbit 1:1000 Cell Signaling Technology 
Polyclonal Akt,  Rabbit 1:1000 Cell Signaling Technology 
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Polyclonal p44/42 MAPK 
(Erk1/2) 
Rabbit 1:1000 Cell Signaling Technology 
Polyclonal p38 MAPK Rabbit 1:1000 Cell Signaling Technology 
Polyclonal SAPK/JNK Rabbit 1:1000 Cell Signaling Technology 
Monoclonal anti-PECAM-1  Rat 1:100 Chemicon 
Polyclonal anti-NOX1 Goat 1:1000 Santa Cruz Biotechnology 
Polyclonal anti-
NOX2/gp91phox 
Rabbit 1:1000 Abcam 
Polyclonal ani-PI 3-kinase 
p110   
Goat 1:500 Santa Cruz Biotechnology 
Polyclonal ani-PI 3-kinase 
p110  
Rabbit 1:500 Santa Cruz Biotechnology 
Polyclonal ani-PI 3-kinase 
p110  
Mouse 1:500 Santa Cruz Biotechnology 
PE-conjugated anti-mouse 
Flk-1 
Rat 1:10 BD Pharmingen 
Phalloidin-Alexa Fluor® 488 A.phalloides 1:100 Invitrogen 
 
3.1.4.2 Secondary antibodies 
Name Dilution Producer 
Anti-PE MicroBeads (isotype: 
mouse IgG1) 
1:10 Miltenyi Biotec 
Goat anti rat IgG, Cy5 conjugate 1:100 Chemicon 
Goat anti-mouse IgG-HRP  1:1000 Santa Cruz Biotechnology
Goat anti-rabbit IgG-HRP 1:1000 Santa Cruz Biotechnology 
Rabbit anti-goat IgG-HRP 1:1000 Santa Cruz Biotechnology 
 
3.1.5 Inhibitors 
Product name Producer 
Akt inhibitor Calbiochem GmbH, Bad Soden, Germany 
Apocynin Sigma-Aldrich GmbH, Taufkirchen, Germany 
2-APT Calbiochem GmbH, Bad Soden, Germany 
Compound 15e  Alexis®Biochemicals GmbH, Lörrach, Germany 
DPI Sigma-Aldrich GmbH, Taufkirchen, Germany 
Rotenone Calbiochem GmbH, Bad Soden, Germany 
Rac1 inhibitor Calbiochem GmbH, Bad Soden, Germany 
VAS2870 Calbiochem GmbH, Bad Soden, Germany 
Wortmannin Sigma-Aldrich GmbH, Taufkirchen, Germany 
 
3.1.6 RT-PCR materiales 
Product name Producer 
DTT 0.1 M Invitrogen GmbH, Karlsruhe,  Germany 
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Desoxyribonucleae I, Amp Grade 
1 U/μl 
Invitrogen GmbH, Karlsruhe,  Germany 
DNase I reaction buffer 10x Invitrogen GmbH, Karlsruhe,  Germany 
dNTP Mix, 10 mM, PCR Grade Invitrogen GmbH, Karlsruhe,  Germany 
EDTA 25 mM Invitrogen GmbH, Karlsruhe,  Germany 
Ethidium bromide 2 
Carl Roth GmbH & Co.KG, Karlsruhe  
Germany 
First-strand buffer 5x Invitrogen GmbH, Karlsruhe,  Germany 
HyperLadder™ IV DNA Ladder Invitrogen GmbH, Karlsruhe,  Germany 
M-MLV reverse transcriptase 200 
U/μl 
Invitrogen GmbH, Karlsruhe,  Germany 
QIAshredder Qiagen GmbH, Hildesheim, Germany 
Random primer oligonucleotides  Invitrogen GmbH, Karlsruhe,  Germany 
Red load taq master 5x Jena Bioscience, Jena, Germany 
TBE buffer 10x Ultra PureTM Invitrogen GmbH, Karlsruhe,  Germany 
 
3.1.6.1 List of primers used in this study for RT-PCR 
Primer  Primer sequence 
Sense 5'-CTG CTC ATT TTG CAA CCG TA-3' NOX1  
Antisense 5'-AGA AG CGA GAG ATC CAT CCA-3 
Sense 5'-ACT GCG GAG AGT TTG GAA GA-3' NOX2  
Antisense 5'-GGT GAT GAC CAC CTT TTG CT-3 
Sense 5'-GAT GGC ACC TGG ACA GTA CAT-3' NOX3 
Antisense 5'- TCT CCT GAG GCT CTG ATG TGT-3' 
Sense 5'-GAT CAC AGA AGG TCC CTA GCA-3' NOX4 
Antisense 5'-GTT GAG GGC ATT CAC CAA GT-3' 
Sense 5'-ACT GTT CAG AGA GGC CAG GA-3' PI3K p110  
Antisense 5'-CGG TTG CCT ACT GGT TCA AT-3' 
Sense 5'-AGC TGG TCT TCG TTT CCT GA-3' PI3k p110  
Antisense 5'-TCC ACC ACG ACT TGA CAC AT-3' 
Sense 5'-CTG ACC CCT CAT CTG ACC AT-3' PI3k p110   
Antisense 5'-TCG TCA GCA TTC ACT TTT CG-3' 
Sense 5'-GAC AAA ACT GGC TCC TCT GC-3' Polymerase II 
Antisense 5'-GCT TGC CCT CTA CAT TCT GC-3' 
 
3.1.7 shRNA materials 
Product name Producer 
Ampicillin  Sigma-Aldrich GmbH, Taufkirchen, Germany 
EndoFree Plasmid Maxi Kit Qiagen GmbH, Hildesheim, Germany 
PEI  Sigma-Aldrich GmbH, Taufkirchen, Germany 
MISSION® Lentiviral Packaging 
Mix 
Sigma-Aldrich GmbH, Taufkirchen, Germany 
MISSION® non-Target shRNA Sigma-Aldrich GmbH, Taufkirchen, Germany 




MISSION® p110  shRNA  Sigma-Aldrich GmbH, Taufkirchen, Germany 
MISSION® NOX1 shRNA  Sigma-Aldrich GmbH, Taufkirchen, Germany 
MISSION® NOX2 shRNA Sigma-Aldrich GmbH, Taufkirchen, Germany 
pLKO.1-puro derivative  
plasmids 
Sigma-Aldrich GmbH, Taufkirchen, Germany 
Penicillin/Steptomycin Biochrom AG, Berlin, Germany 
Polybrene  Sigma-Aldrich GmbH, Taufkirchen, Germany 
Puromycin  Sigma-Aldrich GmbH, Taufkirchen, Germany 
Syringe filter holders (0.2 m) Sartorius AG, Göttingen, Germany 
 
3.1.7.1 Hairpin sequence 
Clone ID Hairpin Sequence (forward-loop-reverse) 
p110  MISSION® shRNA 
NM_008839.1-2719s1c1  5'-gcaacctttatcttgggaatt-ctcgag-aattcccaagataaaggttgc-3' 
NOX1 MISSION® shRNA 
NM_172203.1-882s1c1 5'-cgtgattaccaaggttgtcat-ctcgag-atgacaaccttggtaatcacg-3' 
NOX2 MISSION® shRNA 
NM_007807.2-1153s1c1 5'-gcctggaaactacctaagata-ctcgag-tatcttaggtagtttccaggc- 3' 
 
3.1.8 Consumables materials 
Product name Producer 
Cellstar tissue culture flasks Greiner Bio-One GmbH, Frickenhausen, Germany 
Cellstar® Falcon tubes  
(15 ml, 50 ml) 
Greiner Bio-One GmbH, Frickenhausen, Germany 
Centrifuge tubes Sarstedt AG & Co, Nümbrecht Germany 
Cover slip Menzel GmbH & Co KG, Braunschweig, Germany 
Cryogenic storage vial Fisher Scientific, Schwerte, Germany 
Disinfectant descosept AF Dr. Schumacher GmbH, Malsfeld, Germany 
Disposable pipette Greiner Bio-One GmbH, Frickenhausen, Germany 
Disposable syringes  
Omnifix® 50 ml 
Braun Melsungen AG, Melsungen, Germany 
Microscope slide Menzel GmbH & Co KG, Braunschweig, Germany 
Microcentrifuge tubes  Sarstedt AG & Co, Nümbrecht Germany 
MS Columns Miltenyi GmbH, Bergisch Gladbach 
Petri dish (adherent and  
not adherent) 
Greiner Bio-One GmbH, Frickenhausen, Germany 
Pipette tips Nerbe pluc GmbH, Winsen,  Germany 
Polypropylene tube,  
sterile 15/50 ml 
Greiner Bio-One GmbH, Frickenhausen, Germany 
Precision plus protein  
standard 10-250 kDa 
BioRad GmbH, Dreieich, Germany 
Pre-Separation-Filter Miltenyi GmbH, Bergisch Gladbach 
Protran nitrocellulose  Whatman GmbH, Dassel, Germany 




Serological pipettes  Greiner Bio-One GmbH, Frickenhausen, Germany 
Stericup Millipore GmbH, Schwalbach, Germany 
Sterile filter (0.2 μm) Sartorius AG, Göttingen, Germany 
6/12/24/96-well cell  
culture plate 
Greiner Bio-one GmbH, Frickenhausen 
 
3.1.9 Buffers 
Buffer  Components 
Cell dissociation buffer (IK-buffer) 120 mM NaCl2, 5.4 mM KCl, 5 MgSO4, 5 
mM Na  pyruvate, 1 mM MgCl2, 20 mM Glu-
cose , 20 taurine and 10 mM HEPES  
E1 buffer 135 mM NaCl, 5.4 mM KCl, 1 mM MgCl2, 
10mM glucose, 10 mM HEPES, 1.8 mM 
CaCl2, pH 7.5 
FACS buffer PBS 1x, 2% FBS 
Lysis buffer 20 mM Tris-HCl pH 7.5, 1% Triton X-100, 1 
mM EDTA, 1 mM phenylmethylsulfonyl 
fluoride, 1 mM DTT, 10 μg/ml aprotinin, 5 
μg/ml pepstatin A, 25 μg/ml leupeptin, 1 mM 
sodium vanadate, 10 μl/ml Phosphatase In-
hibitor cocktail 3 
MACS buffer 0,5 mM FBS, 2 mM EDTA in PBS 
PBS 1x 137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.76 mM K2HPO4, pH 7.4 
PBS-Triton 1% 1% Triton X-100 in 1x PBS 
PBS-Tween 0.1% 1x PBS, 0.1% Tween 20 
PFA 4% buffer 4% PFA in 1x PBS 
Resolving gel 40% acrylamide, 1.5 M Tris-HCl (pH 8.8), 
10% SDS, dH2O, 10% APS, TEMED 
5x SDS-PAGE electrophoresis 
buffer 
25 mM Tris-base, 200 mM glycine, 0.1% 
SDS 
SDS-PAGE loading buffer 0.5 M Tris (pH 6.8), 10% SDS, 99% glycerol, 
DTT, carbamide/ urea, bromophenol blue 
Stacking gel 4% 40% acrylamide, 0.5 Tris-HCl (pH 6.8), 10% 
SDS, dH2O, 10% APS, TEMED 
Stripping buffer 20 ml SDS 10%,12.5 ml 0.5 MTris-HCl pH 
6.8, 0.8 ß-mercaptoethanol, 67.5 dH2O 
Transfer buffer 25 mM Tris base, 192 mM glycine, 20% 
methanol 
1.5 M Tris-HCl, pH 8.8 54.5 g Tris base, pH to 8.8, 300 ml dH2O. 
0.5 M Tris-HCl, pH 6.8 12.1 g Tris base, pH to 6.8, 200 ml dH2O. 
1x TBS  50 mM Tris-Cl, 150 mMNaCl, pH 7.5 
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3.1.10 Cell culture media  
3.1.10.1 Basic components and supplements 
Product name Producer 
Basal Iscove Biochrom AG, Berlin, Germany 
DMEM Invitrogen GmbH, Karlsruhe,  Germany 
FBS Sigma-Aldrich GmbH, München, Germany 
Ham's F-10 Biochrom AG, Berlin, Germany 
GMEM Sigma-Aldrich GmbH, Taufkirchen, Germany 
LIF Millipore GmbH, Schwalbach, Germany 
LB-Broth base  Invitrogen GmbH, Karlsruhe,  Germany 
L-glutamine Biochrom AG, Berlin, Germany 
-mercaptoethanol Sigma-Aldrich GmbH, München 
NEAA Biochrom AG, Berlin, Germany 
Sodium pyruvate Biochrom AG, Berlin, Germany 
Trypsin-EDTA (0.25%),  
phenol red 
Invitrogen GmbH, Karlsruhe,  Germany 
 
3.1.10.2 Composition of cell culture media  
Medium  Components 
CGR8-Culture medium  25 ml GMEM 
2,5 ml heat-inactived FBS 
12,5 l ß-mercaptoethanol (70.4 μl ß-
mercaptoethanol in 10 ml PBS sterile) 
250 l L-glutamine 
250 l LIF, (103 U/ml LIF) 
CGR8-Differentiation medium 
 
500 ml Basal Iscove Medium w/o L-glutamin  
100 ml heat-inactived FBS 
0,5 ml ß-mercaptoethanol (70.4 μl ß-
mercaptoethanol in 10 ml PBS sterile) 
 6,25 ml L-glutamine 
6,25 ml NEAA 
CGR8-Freezing medium 
 
45 ml CGR8 differentiation medium 
5 ml DMSO 
HEK293T-Culture medium 500 ml DMEM 
50 ml heat-inactived FBS 
5 ml L-glutamine 
5 ml NEAA 
2,5 ml Penicillin/Steptomycin 
DU-145 -Culture medium 500 ml Ham's F-10 medium  
50 ml heat-inactived FBS 
 5 ml L-glutamine  
5 ml -mercaptoethanol (140 μl ß-
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mercaptoethanol in 200 ml PBS sterile) 
5 ml NEAA 
2.5 ml Penicillin/Steptomycin 
E. coli.-Culture medium  
(LB-Medium) 
1 liter dH2O  
20 g LB Broth Base (Lennox L Broth Base) 
Ampicillin (100 g/ml) 
 
3.1.11 Cell lines 
3.1.11.1 CGR8 ES cell line (ECACC, Salisbury, UK) 
CGR8 ES cell line was established from the inner cell mass of a 3.5 day male pre-
implanted mouse embryo (Mus musculus, strain 129). These pluripotent cells were 
retained the ability to participate in normal embryonic development. Differentiation 
of CGR8 cell was inhibited by the leukaemia inhibiting factor (LIF) which is identi-
cal to pleiotropic cytokine differentiation inhibiting activity (DIA)(Nichols et al. 
1990, Robertson et al. 1993).  
 
3.1.11.2 DU-145 cell line was a kind gift of Dr. J. Carlsson (Uppsala, Sweden) 
DU-145 cell line was established from the tumor tissue removed from the metastatic 
central nervous system lesion of a 69-year-old man with prostate carcinoma (Stone et 
al. 1978). The cells are epithelial, grow in isolated islands on plastic Petri dishes, and 
form embryoied bodies in spinner flask culture (Wartenberg et al. 1998b). 
 
3.1.11.3 HEK293T cell line (German Collection of Microorganisms and Cell 
Cultures (DSMZ) 
Human Embryonic Kidney (HEK) 293T cells were originally derived from human 
embryonic kidney (HEK) of healthy aborted fetus. Then HEK 293 cells were gener-
ated in the early 70s by transformation of cultures of normal HEK cells with DNA 
from human adenovirus type 5 (Graham et al. 1977, Graham and van der Eb 1973). 
The HEK293T cell line was derived from HEK 293 cell line by inserted the gene for 
T-antigen of Simian Virus 40 (SV40) (Naldini et al. 1996).  
 
3.1.12 Bacteria  
Strain Genotype Source 
E.coli DH5  F-, 80dlacZ M15, (lacZYA-argF)U169, deoR, re-









3.2.1 ES cells and embryoid body culture 
The pluripotent ES cell line CGR8 was obtained from European Collection of Cell 
Cultures (ECACC, UK). The CGR8 cell line was cultured on gelatine-coated cell 
culture flask (0.1% gelatine in distilled water) in GMEM plus LIF in a humidified 
environment containing 5% CO2 at 37°C. ES cells were routinely passaged every 2 
days. Cells were covered with 2 ml of  trypsin-EDTA solution, then returned to 37°C 
incubator for 1-2 minutes or until cells were uniformly dispersed into single cells. 9 
ml of ES cells medium were added to inactivate the Trypsin. At day 0 of differentia-
tion, adherent cells were enzymatically dissociated using trypsin-EDTA. To generate 
the embryoid bodies, a total of 1  107 cells were seeded in 250 ml siliconized (sig-
macot, Sigma-Aldrich) spinner flasks containing 125 ml CGR8-differentiation me-
dium. After 24 hrs, 125 ml medium was added to give a final volume of 250 ml. The 
spinner flask medium was stirred at 22.5 r.p.m. using a cell-spin stirrer system  and 
125 ml cell culture medium were exchanged every day as previously described 
(Wartenberg et al. 1998a). The spinner flask culture technique proved to be efficient, 
especially for the differentiation of cells of the endothelial and the cardiac lineage. 
Over 50% of the embryoid bodies manifested into beating cardiomyocytes on day 8, 
and 100% embryoid bodies showed proper development of vascular-like structures 
within the embryoid bodies (Wartenberg et al. 1998a). At day four of spinner flask 
cultivation, embryoid bodies were removed from the spinner flask and placed in non-
adherent bacteriological petri dishes for incubation with the various substances.  
3.2.2 Thawing and freezing of CGR8 cells 
Since DMSO can induce the differentiation of ES cells. Cells must be thawed late in 
the thawing day and the medium must be changed the following morning to mini-
mize the effects of residual DMSO. Cells were thawed quickly in 37°C water bath. 
Afterwards they were diluted into prewarmed ES cell medium 10 ml and gently 
mixed. After centrifugation medium above the pellet was removed and cells were 
resuspended in 6 ml of prewarmed GMEM medium plus LIF and plated into a gela-
tine-coated culture flask at 37°C in a humidified 5% CO2 incubator.  
For freezing the CGR8 cells, the cells were trypsinized and resuspended in complete 
medium and gently centrifuged (800 rpm, 4 min). The medium above the pellet was 
removed and upto 1 x 107 cells/ml were re-suspended in 3 ml CGR8 freezing me-
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dium. Cells were aliquoted into three Cryo-vials. The vials were frozen at -80°C 
overnight then transferred to liquid nitrogen for long-term storage. 
3.2.3 Culture technique of multicellular spheroids 
The human prostate cancer cell line DU-145 was grown routinely in 5% CO2, hu-
midified air at 37 C with DU-145-Culture medium. Cell monolayers were enzymati-
cally dissociated with  trypsin-EDTA and seeded in siliconized 250 ml spinner flasks  
with 250 ml of Ham's F-10 complete medium using a Cell-spin stirrer system as de-
scribed previously (Wartenberg et al. 2001). Cell culture medium was partially (100 
ml) changed every day.  
 
3.2.4 Cultivation of HEK293T  
The Human Embryonic Kidney (HEK293T) cell line is for use in facilitating optimal 
lentivirus production. The HEK293T cell line is an HEK 293 derived cell line that 
expresses the SV40 large T-antigen (Naldini et al. 1996). T-antigen can also bind to 
several proteins which inhibit cell cycle. So the cell is forced entering into more 
number of cell cycle (Bednarz et al. 2000). This adds on to increase the amplification 
of the transfected plasmid thus increasing the efficiency of transfection, higher vector 
production and higher transduction efficiency. HEK293T cells were cultured in a 
complete DMEM medium at 37ºC with 5% CO2.  
 
3.2.5 pLKO.1-puro vector description and features  
Features of the pLKO.1-puro vector allow for transient or stable transfection of the 
shRNA as well as production of lentiviral particles (Stewart et al. 2003). Stable gene 
silencing is selected using the puromycin selectable marker while self-inactivating 
replication incompetent viral particles can be produced in packaging cells 
(HEK293T) by co-transfection with compatible packaging plasmids (Zufferey et al. 
1998, Zufferey et al. 1997). Lentiviral based particles permit efficient infection and 
integration of the specific shRNA construct into differentiated and non-dividing cells 
and provides long-term knockdown. The length of the pLKO.1-puro plasmid is 7,086 
bp, as indicated in the vector map below (Fig. 2.1). Without an shRNA insert, 
pLKO.1-puro vector has a length of 7,052 bp. 




Figure 3.1: Map of pLKO.1 containing an shRNA insert. Abbreviations: Cppt, 
Central polypurine tract: hPGK, Human phosphoglycerate kinase eukaryotic pro-
moter, puroR, Puromycin resistance gene for mammalian selection, SIN/LTR, 3' self 
inactivating long terminal repeat, f1 ori, f1 origin of replication, ampR, Ampicillin 
resistance gene for bacterial selection, pUC ori, pUC origin of replication, 5' LTR, 5' 
long terminal repeat, Psi,   RNA packaging signal, RRE, Rev response element 
(http://www.sigmaaldrich.com/RNAi). 
 
3.2.6 Competent cells and plasmids transformation 
The Escherichia coli (E.Coli) strains DH5  was used for propagation of plasmid 
constructs. Bacterial cells E.Coli DH5  were grown in Luria-Bertani (LB) Broth 
Base or on LB-Agar supplemented with ampicillin antibiotics according to the meth-
od previously described by Hanahan 1983 (Hanahan 1983). For each transformation, 
2 μl of DNA was added to 100 l of E.Coli competent cells in electroporation cu-
vette and incubated on ice for 20 minutes, followed by electroporation using 
AMAXA Nucleofector system. The cells were allowed to recover in 1 ml LB-
Medium and then incubated for 1h at 37°C. 50 μl of bacterial culture were plated on 
LB-Agar plate containing ampicillin antibiotics (50 g/ml) and incubated at 37°C 
overnight to select the transformants. E. coli cells containing the recombinant plas-
mids were inoculated into 10 ml of LB- Medium containing 50 g/ml ampicillin at 
37°C 8 h in a shaker. Then 0.5 ml of each cultures were transferred to 250 ml of 
fresh LB-Medium containing 50 g/ml ampicillin and were grown at 37 ºC overnight 
in a shaker. 
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3.2.7 Isolation of plasmid DNA from 
Large-scale plasmid DNA isolation was carried out using EndoFree Plasmid Maxi 
Kit (Qiagen) as per the manufacturer’s protocol (Qiagen). Cells were harvested by 
centrifugation (5000g for 1 h at 4 ºC) and re-suspended in solution P1 (50 mM Tris-
Cl, pH 8.0, 10 mM EDTA, 100 ug/mL RNase A) with gentle vortexing and then 
lysed with solution P2 (200 mM NaOH, 1% SDS), SDS breaks apart the lipid mem-
branes and solubilizes cellular proteins, NaOH denatures DNA (both plasmid and 
genomic). After 5 min solution P3 (3.0 M potassium acetate, pH 4.8) was then added 
with strongly mix to neutralize the acidic pH. The supernatant containing plasmid 
DNA was filtered by QIAfilter Cartidge into a clean tube and incubated 30 min on 
ice with endotoxin removal (ER) buffer to prevent lipopolysacharide (LPS) mole-
cules from binding to the resin in the QIAGEN-tips. For plasmid DNA binding the 
mixture was transferred into QIAGEN-tip and allowed it to enter the resin by gravity 
flow. Then all the contaminants in the plasmid preparations were removed by wash-
ing three times with buffer QC (1.0 M NaCl, 50 mM MOPS, pH 7.0, 15% isopropa-
nol) by allowed the buffer to move through the QIAGEN-tip by gravity flow.  For 
eluting DNA buffer QN (1.25M NaCl, 50mM Tris-Cl, pH 8.5, 15% isopropanol) was 
added to the column and allowed to drain by gravity flow in a endotoxin-free or py-
rogen-free tube. Cold isopropanol was added to the eluting DNA then was centri-
fuged at 15000g for 30 min at 4 ºC. The supernatant was discarded and the pellet was 
rinsed with cold 70% ethanol and centrifuged at 15000g for 10 min. Then, the pellet 
was dried for 5-10 min and dissolved in a suitable volume of endotoxin-free Buffer 
TE (10 mM Tris-Cl, pH 8.0, 1 mM EDTA). 
 
3.2.8 The shRNA mediated down regulation of p110  and NOX  
In order to study the function of particular proteins stable small hairpin RNA 
(shRNA)-mediated down-regulation of gene expression has been proven to be a 
powerful tool. pLKO.1-puro (Sigma-Aldrich) derivative plasmids encoding shRNA 
sequence targeting murine PI3K p110  catalytic subunit, murine NOX1 and NOX2 
or a non-targeting control shRNA were separately introduced into CGR8 ES cells by 
lentiviral particles, which showed advantage to infect the proliferating and quiescent 
cells compared to other delivery system (Manjila et al. 2013). Ecotropic lentiviral 
particles were generated using Human Embryonic Kidney (HEK293T) based packag-
ing cells. In order to obtain high viral titers Phoenix packaging cell was cultured to 
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70% confluency at 37 C. 100% confluence should be prevented. For a 10 cm dish, 
lentiviral vector plasmid (10 g) were cotransfected with plasmids encoding the 
HIV-Rev (5 g), HIV-MDL (10 g) and the ecotropic envelope (2 g) in the pres-
ence of PEI (70 g). Supernatants were harvested after 24 h and 48 h and filtrated 
through 0.25 μm filters (Schambach et al. 2006). The viral particles were stored at 
4 C for several days and for long-term at -80 C. Lentiviral particles were added to 
CGR8 ES cells which were plated in a well of a 6-well plate with polybrene (8 
μg/ml) to enhances efficiency of virus infection, centrifuged at 400 g in a cell culture 
centrifuge for 1 h and replaced with fresh medium on the following day. A total of 
three (24 + 36 + 48 hrs) infection rounds were carried out. On the following day the 
cells were selected with 2 g/ml puromycin for 10-14 days. Down regulation of 
PI3K p110 catalytic subunit p110 , NOX1 and NOX2 was analysed by RT-PCR and 
western blot (Bartsch et al. 2011, Bekhite et al. 2011, Milosevic et al. 2010). 
 
3.2.9 Magnetic cell separation (MACS) and flow cytometry (FCM) analysis 
Embryoid bodies were generated and cultivated as described above. 4-day-old em-
bryoid bodies were dissociated by incubation with collagenase type II (2 mg/ml) dis-
solved in cell dissociation buffer (IK-buffer) at 37°C for 5-10 minutes. For cell sepa-
ration MACS separation columns were used. The separation procedure was carried 
out using a PE-conjugated rat anti-mouse Flk-1 antibody (dilution 1:10). For label-
ling anti-PE MicroBeads (Miltenyi Biotec) was used. Cells from the positive selected 
fraction were plated and incubated at 37°C and 5% CO2 for starting the respective 
co-incubation experiments. Purity analysis was carried out using a FACSCalibur 
with a scanning wave length of 488 nm (PE-labelled cells) and a detection wave 
length of 575 nm.  
 
3.2.10 Treatment with inhibitors  
To investigate the role of the PI3K in vascular differentiation, embryoid bodies de-
rived from ES cells were incubated in the presence or absence of VEGF-165 (500 
pM) (Sigma-Aldrich) with pan PI3K inhibitor wortmannin (1 μM), or with the p110  
inhibitor of catalytic subunit compound 15e (0.5 μM) (Bekhite et al. 2011, 
Hayakawa et al. 2006). We also used DPI (10 μM) or VAS2870 (50 μM) the pan 
inhibitors for NADPH, the novel NOX1 inhibitor 2-APT (0,5 μM), apocynin (100 
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μM), the respiratory chain complex I inhibitor rotenone (2.5 μM), Rac1 inhibitor (50 
μM) and Akt inhibitor (50 μM) as shown in the results section. 
 
3.2.11 Immunofluorescence staining and quantitative analysis  
Blood vessels like structures in embryoid bodies were identified by immunolabeling 
platelet endothelial cell adhesion molecule (PECAM-1, CD31). Embryoid bodies 
were fixed in methanol-acetone (7:3) for 1 h at -20°C and were subsequently perme-
abilized for 10 min with phosphate-buffered saline (PBS) supplemented with 1% 
Triton X-100 (PBST). Fluorescence recordings were performed using a confocal 
laser scanning microscope (LSM 510) connected to an inverted microscope (Axiovert 
135). Quantitative IF was analysed as previously described (Sauer et al. 2005) using 
an Axiovision software tool. Briefly, images (512 x 512 pixels) were acquired from 
PECAM-1-stained embryoid bodies corrected for background fluorescence using the 
extended depth of focus algorithm of the confocal setup. Generally 4 full frame im-
ages separated by a distance of 8 μm in the z-direction were recorded that included 
the information of the capillary area and spatial organization in a tissue slice 32 μm 
thick. From the acquired images an overlay image of the vascular structures in the 
scanned tissue slice was generated.  By use of the image analysis facilities of the con-
focal setup the antigen-positive vascular areas within the three-dimensional projec-
tion of vascular structures were identified in the embryoid bodies. 
To investigate the changes in actin structures during the migration process, we used 
cytoskeleton staining by phalloidin-Alexa Fluor® 488. Flk-1+ cells were grown on 
cover glass in 24-wells up to semi confluence and stimulated with VEGF (500 pM) 
or media alone for 30 min. Then the cells were fixed with 4% paraformaldehyde for 
1h on ice, and stained with phalloidin- Alexa Fluor 488 for 30 min at room tempera-
ture in dark and analyzed by LSM. Nuclei were stained with 4 ',6-diamidino-2-
phenylindole (DAPI) before covering the slides. DAPI is binds selectively to DNA 
and thus colours the content of the nucleus of the cell. Results are bright blue fluo-
rescence nuclei (excitation maximum at 340 nm, emission maximum at 488 nm), 
which is helpful for finding the best focus during microscope scanning. 
 
3.2.12 Measurement of ROS  
Intracellular ROS levels were measured using the fluorescent dye 2`,7`- dichlorodi-
hydrofluorescein diacetate (H2DCF-DA), which is a nonpolar compound that is con-
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verted into a nonfluorescent polar derivative 2`,7`- dichlorodihydrofluorescein 
(H2DCF) by intracellular esterase. H2DCF is membrane impermeable and is rapidly 
oxidized to the highly fluorescent 2`,7`-dichlorofluorescein (DCF) in the presence of 
intracellular ROS. For the experiments, embryoid bodies were incubated in serum-
free medium and 20 μM H2DCF-DA was added. After 20 min, intracellular DCF 
fluorescence was evaluated by the LSM 510 (Milosevic et al. 2010).  
 
3.2.13 Measurement of intracellular superoxide 
Intracellular generation of superoxide (O2-) was estimated using the superoxide indi-
cator dihydroethidium (DHE), which can be used specifically for measuring intracel-
lular O2-. Cytosolic DHE exhibits blue fluorescence. However, once this probe is 
oxidized to ethidium it intercalates into chromosomal DNA, staining its nucleus with 
brightly red fluorescence. Washed ES cells were pre-incubated with 10 μM DHE for 
20 min at 37°C in darkness and then rinsed with E1-buffer to remove excess dye. For 
fluorescence excitation, the 488-nm band of the argon ion laser of the LSM 510 
(Zeiss) was used. Emission was recorded using a longpass LP515-nm filter set. 
 
3.2.14 RNA isolation and reverse transcription-polymerase chain reaction (RT-
PCR) 
Total RNA isolation from ES cells was performed using the RNeasy Mini Kit (Qi-
agen) according to the manufacturer’s recommended procedures followed by ge-
nomic DNA digestion using DNaseI (Invitrogen). cDNA was synthesized from 2 μg 
total RNA using a Superscript II reverse transcriptase (Invitrogen) according to man-
ufacturer’s instructions using random primer. The RT product was diluted 1:10 and 
PCR was performed using the primers (Sigma) indicated in material with 40 cycles 
performed at 58°C annealing temperature. Gel images and visualising bands were 
performed by GenSnap from SynGene (VWR) using a 1% agarose gel (SERVA). 
 
3.2.15 Western blot assay 
ES cells were washed in ice cold PBS and subsequently lysed in lysis buffer for 30 
min on ice. Samples were centrifuged at 13.000 g for 10 min to pellet the debris. Af-
ter determination of protein concentrations using the method of Bradford, 40 μg of 
protein per sample was heated to 95°C for 10 min with SDS-PAGE loading buffer 
and separated in SDS polyacrylamide gels and transferred to nitrocellulose mem-
MATERIAL AND METHODS 
 
30 
branes in transfer buffer at 20 V over 10 h. Membranes were blocked with 10% 
(wt/volume) dry fat-free milk powder in Tris-buffered saline with 0.1% Tween 
(TBST) for 3 h at 4 C. Incubation with primary antibodies was performed at 4 °C 
overnight. Subsequently, membranes were washed with 0.1% TBST. For secondary 
antibody reaction, membranes were incubated with the adequate horseradish peroxi-
dase (HRP) conjugated secondary antibodies (Santa Cruz) for 60 min at room tem-
perature. Corresponding bands were visualised using the ECL detection kit (Amer-
sham). Chemiluminescence signals were quantified using a charge coupled device 
(CCD) camera-based chemiluminescence detection system (LAS 3000). 
 
3.2.16 Angiogenesis assay
Matrigel (BD Biosciences) was added to 96-well plates on ice and allowed to polym-
erize for 1 h at 37°C. The isolated Flk-1+ cells from 4-days-old embryoid bodies in-
cubated in CGR8 medium for one day were harvested after trypsin-EDTA treatment, 
resuspended in CGR8 medium in the presence or absence of VEGF, plated onto the 
Matrigel at a density of 10000 cells/well. Matrigel cultures were incubated at 37°C 
and photographed after 16 hours.  
 
3.2.17 Scratch migration assay 
To assess whether p110  and NOX1 play a role in cell migration of Flk-1+ cells, a 
scratch cell migration assay was performed in 12-well tissue culture plates coated 
with 0.1% gelatine for a minimum of 2 h at 37°C. Upon reaching 80-90 % conflu-
ence, the Flk-1+ cells were scratched using a pipette tip and cell debris was removed. 
Cells were cultured for 6 h, to allow for cell migration in the presence or absence of 
VEGF. Each treatment was performed in triplicate wells, and the mean distance of 
migrating cells in each well was measured from five randomly chosen fields under 
light microscopy at 0 h and 6 h (Bhattacharya et al. 2009).  
 
3.2.18 Long-term labelling of multicellular tumor spheroids 
To discriminate tumor spheroids grown in confrontation culture from embryoid bod-
ies, tumor spheroids were labeled with the long-term cell tracker dye 5-
chloromethylfluorescein diacetate (CMFDA) (Invitrogen). In brief, tumor spheroids 
were incubated for 1 h in F10 cell culture medium that contained 10 μm CMFDA 
(stock solution 10 mm, dissolved in DMSO). Subsequently, spheroids were washed 
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and incubated for a further 24 hours in bacteriologic Petri dishes. Stable CMF fluo-
rescence was observed for more than 5 days of tumor spheroid culture (Wartenberg 
et al. 2003). Fluorescence excitation was performed by the 488-nm line of an argon-
ion laser of the confocal setup. Emission was recorded using a longpass LP515-nm 
filter set. 
3.2.19 Generation of confrontation cultures 
Confrontation cultures are tissues generated by culturing three-dimensional tumor 
spheroids and embryoid bodies in close contact. After few days the tumor spheroid is 
vascularised by the embryoid body through tumor-induced angiogenesis (Wartenberg 
et al. 2003). For the generation of confrontation cultures, multicellular tumor sphe-
roids and embryoid bodies were removed from spinner flasks. To discriminate tumor 
spheroids grown in confrontation culture from embryoid bodies, tumor spheroids 
were labelled with CMFDA as described previously. One embryoid body (6-days-
old) and one tumor spheroid (20-days-old) were inoculated in a 35 μl drop of mixed 
culture medium (50 % DU145 medium, 50 % CGR8 medium) placed onto the lid of 
a 10 cm Petri dish. The lid was turned around and placed on the Petri dish, which 
was filled with 15 ml of sterile PBS. Within 48 hours, embryoid bodies and tumor 
spheroids closely attached within the hanging drops and were subsequently trans-
ferred to 10-cm bacteriologic Petri dishes filled with 10 ml of CGR8 medium. PE-
CAM-1 and CMFDA fluorescence recordings were performed by LSM 510 (Carl 
Zeiss, Germany).  
 
3.2.20 Statistical analysis  
Data were expressed as mean values ± SD with n denoting the number of 3 experi-
ments unless otherwise indicated. In each experiment at least 15 embryoid bodies 
were analyzed. GraphPad InStat-3 software (GraphPad Software Inc., San Diego, 
USA) was applied for One-way ANOVA or t-test of unpaired data. Data are ex-
pressed as fold or percentage of expression relative to control values. Differences 
were considered statistically significant at a p value of <0.05. The graphical repre-





4.1 Class IA PI3Ks catalytic subunit p110 , Flk-1 and PECAM-1 production 
during ES cell differentiation 
To investigate the differentiation dependent appearance of the class IA PI3K p110  
catalytic subunit in embryoid bodies during vascular differentiation, the protein level 
of p110 , Flk-1and PECAM-1 was examined using western blot analysis. This anal-
ysis was performed from day 2 to day 10 of embryoid body culture (Fig. 4.1A). In-
terestingly, we found that embryoid bodies significantly produce p110  and Flk-1 
before day 4 of culture. Moreover, the highest increase of p110  occurs at day 4 of 
ES cell differentiation in parallel to Flk-1, which is a marker of cardiovascular pro-
genitor cells (Choi et al. 1998), the production level of Flk-1 declined during subse-
quent days, while p110  remained constant till day 7 (Fig. 4.1A). Furthermore, a 
significant increase of PECAM-1 production was observed in a time frame between 
day 6 and day 10 of culture (Fig. 4.1A). Moreover, the level of endogenous ROS was 
up-regulated from day 4 of culture and remained elevated till day 6 (Fig. 4.1B). 
Therefore it can be concluded that a significant synchronicity of endothelial cell 
commitment with the appearance of class IA PI3K catalytic subunit p110  and ROS 
occurred during ES cell differentiation. Thus it is reasonable to assume that p110  

































Figure 4.1: Production of class IA PI3K catalytic subunit p110  and ROS during vas-
cular differentiation. (A), western blot analysis of catalytic subunit p110 , Flk-1 and PE-
CAM-1. Whole cell lysates were blotted at indicated time points. GAPDH was used as an 
internal standard. The blots shown are representative for at least 3 experiments with consis-
tent results. Graphs under the blots shows mean values (+/- standard deviation). (B), endoge-
nous ROS generation during ES cell differentiation. ROS production was analysed using 
image analysis facilities of the LSM 510. Results are based on three independent experi-
ments. 
 
4.2 Silencing of PI3Ks class IA p110 catalytic subunits and NOX using shRNA 
technology 
To obtain stable down regulation or inhibition of p110 , NOX1 and NOX2 we used 
stable short hairpin RNA (shRNA) targeting PI3K catalytic subunit p110 , NOX1 
and NOX2. For these experiments undifferentiated CGR8 cells were transduced with 
the respective shRNA which was introduced in the pLKO.1 vector. The level of inhi-
bition of p110  subunit (Fig. 4.2A), NOX1 (Fig. 4.2B) and NOX2 (Fig. 4.2C) were 
analysed by western blot in 5-day-old embryoid bodies (Fig. 4.2A-C). The shRNA 
cells significantly reduced p110 , NOX1 and NOX2 protein production compared to 
shRNA control (pLKO.1) cells (Fig. 4.2A-C). Interestingly, no interfere was showed 











































































Figure 4.2: Analysis of proteins production for gene-inactivated embryoid bodies. The 
blots shown are representative for at least 3 experiments with consistent results. Graphs un-
der the blots shows mean values (+/- standard deviation) of 3 independent experiments. 
GAPDH was used as an internal standard. (A), embryoid bodies showed specific and signifi-
cant inhibition of the phosphoinositide 3-kinase (PI3K) catalytic subunit p110  using short 
hairpin RNA (shRNA) without interfering the production of p110  and p110 . (B), embryoid 
bodies showed specific and significant inhibition of the NOX1 using shRNA without inter-
fering the production of NOX2 and NOX4. (C), embryoid bodies showed specific and sig-
nificant inhibition of the NOX2 using shRNA without interfering the production of NOX1 
and NOX4.   *P < 0.05, statistically significant as indicated, n. s. not significant.  
 
4.3 Flk-1+ cells derived from differentiated ES cells produce NOX isoforms and 
PI3Ks class IA p110 catalytic subunits 
To examine whether members of the NADPH oxidase family are produced in vascu-
lar progenitor cells, Flk-1+ cells were isolated from 4-day-old embryoid bodies by 
magnetic cell sorting (MACS). Flow cytometry (FCM) analysis for Flk-1+ cell after 
sorting resulted in a purity of approximately 95.7% Flk-1+ cells (Fig. 4.3A). More-
over, the relative mRNA and protein production level of NOX isoforms was exam-
ined using RT-PCR and western blot analysis (Fig. 4.3D-F). Results from mRNA 
(Fig. 4.3B,C) and western blot (Fig. 4.3D,F) analysis showed that Flk-1+ cells mainly 
produced NOX1 and NOX4 (Fig. 4.3B-F), whereas NOX2 was scarcely produced in 
Flk-1+ cells (Fig. 4.3B,E). In contrast, NOX3 was not produced in Flk-1+ cells iso-
lated from 4-day-old embryoid bodies (Fig. 4.3C). Furthermore, the production of 
PI3K class IA p110 catalytic subunits in the Flk-1+ cells was analysed. The results 
showed that PI3K class IA p110 catalytic subunits (p110 ,  and ) were signifi-
cantly produced in Flk-1+ cells (Fig. 4.3G). These findings indicate that the catalytic 






















































































































































































































































Figure 4.3: Purity of vascular progenitor cells isolated from embryoid bodies and ex-
pression of NOX and p110 in ES cells. Flk-1 positive cells were MACS sorted from 4-day-
old embryoid bodies. (A), Flk1 cells were labelled using PE-conjugated rat anti-mouse Flk-1 
antibody and processed by FCM. Cells of 4-day-old embryoid bodies were MACS sorted 
and analysed for mRNA levels using RT-PCR. mRNA of NOX1 and NOX2 (B), NOX3 and 
NOX4 (C) of 4-day-old sorted Flk1 positive, negative and unsorted cells was amplified using 
RT-PCR and processed by DNA agarose gel electrophoresis. Polymerase II was used as 
internal standard. Representative gels for at least 3 repeated experiments are demonstrated. 
Graphs under the blot show mean values (+/- standard deviation) of 3 independent experi-
ments. Specific mRNA level was calculated in relation to Polymerase II. GAPDH was used 
as an internal standard for western blot analysis of NOX1 (D), NOX2 (E) and NOX4 (F). 



































































































































































under the blots shows mean values (+/- standard deviation). (G), mRNA of the class IA PI3K 
catalytic subunit (p110 , , ).  *P < 0.05, statistically significant as indicated, n. s. not sig-
nificant. 
 
4.4 VEGF induces ROS production mediated by NADPH oxidases 
It has been shown that ROS such as hydrogen peroxide (H2O2) and superoxide (O2-) 
are created as a result of normal cellular signaling and metabolism (Becker 2004). 
Interestingly, our previous report demonstrated a link between ROS and vascular 
differentiation (Bekhite et al. 2010). According to the working hypothesis of the pre-
sent study VEGF may stimulate vasculogenesis/angiogenesis in the ES cell derived 
embryoid bodies by stimulating ROS production through PI3K. Using H2DCF as a 
fluorescent ROS indicator it was demonstrated that VEGF (500 pM) significantly 
increased ROS generation in 4-day-old embryoid bodies (Fig. 4.4A,B). However, no 
increase in ROS was observed when embryoid bodies were incubated with NADPH 
oxidase inhibitors DPI (10 μM) or VAS2870 (50 μM) as well as with apocynin (100 
μM) (Fig. 4.4A,B). In contrast, co-incubation the embryoid bodies with rotenone (10 
μM), a mitochondrial inhibitor, could not abolish the effect of VEGF on ROS gen-
eration, thus suggesting a distinct source of ROS from NADPH oxidase (see Fig. 
4.4A,B). Furthermore, inhibition the ROS generation by apocynin suggests an impact 
of the NOX1 and NOX2 in the ROS production in the ES cells (Fig. 4.4A,B). 
To investigate the involvement of class IA PI3K , NOX1 and NOX2 in VEGF stim-
ulated ROS generation in ES cells, we treated 5-day-old shRNA p110 , shRNA 
NOX1 and shRNA NOX2 embryoid bodies with VEGF. In shRNA p110  and 
shRNA NOX1 embryoid bodies VEGF treatment failed to increase ROS whereas 
ROS generation was not affected in shRNA NOX2 embryoid bodies (Fig. 4.4C,D). 
Thus our data indicate that p110  and NOX1 but not NOX2 are involved in ROS 








Figure 4.4: VEGF induced ROS production in embryoid bodies. 5-day-old embryoid 
bodies were stimulated by VEGF (500 pM) for 30 min. ROS production of cells was meas-
ured using the fluorescent dye 2`,7`- dichlorodihydrofluorescein diacetate (H2DCF-DA). (A), 
images show DCF fluorescence of embryoid bodies treated with NADPH oxidase inhibitors 
DPI (10 M), VAS2780 (50 μM) or apocynin (100 M) or respiratory chain complex I in-
hibitor rotenone on VEGF-induced ROS generation as indicated. Bars represent 100 μm. 
(B), graph under the image shows mean values (+/- standard deviation) of ROS generation 




























































































and apocynin completely inhibited ROS generation in embryoid bodies upon VEGF treat-
ment, whereas rotenone did not affect the ROS generation. (C), images show DCF fluores-
cence of embryoid bodies depleted for p110 , NOX1, NOX2 or wild type (pLKO.1) treated 
with VEGF. Bars represent 100 μm. (D), VEGF failed to increase the ROS generation in 
p110  and NOX1 shRNA gene-inactivated embryoid bodies in comparison to pLKO.1 em-
bryoid bodies. *P < 0.05, statistically significant as indicated, n. s. not significant. 
 
4.5 VEGF induced O2- production is dependent on PI3K-Rac1 activation in  
Flk-1+ cells 
To confirm experiments with the non-specific ROS indicator H2DCF additional ex-
periments were performed for measuring intracellular O2- (Carter et al. 1994). VEGF 
(500 pM) and DHE (10 μM) were added and 20 min after stimulation incubation at 
37ºC, the cells were examined microscopically. As shown in Figure 4.5, VEGF 
treatment strongly elevated O2- generation in plated Flk-1+ cells isolated from 4-day-
old embryoid bodies whereas O2- remained at the control level when the Flk-1+ cells 
were isolated from shRNA p110  or shRNA NOX1 embryoid bodies (Fig. 4.5A). 
Moreover, to determine whether the ROS production is dependent on Rac1, Rac1 
inhibitor (50 M) was used. The results shown in Figure 4.5A demonstrate that 
VEGF did not increase O2- production upon pharmacological inhibition of Rac1. 
Furthermore, we investigated whether NOX2 deficiency in Flk-1+ cells has an impact 
on O2- production upon VEGF treatment. For this purpose, we quantified the DHE 
fluorescence in both untreated and VEGF-treated Flk-1+ cells (Fig. 4.5B). As shown 
in Figure 4.5B, knockdown of NOX1 in Flk-1+ cells abolished the effects of VEGF 
on O2- production. In contrast, knockdown NOX2 in Flk-1+ cells showed no signifi-
cant effects on O2- production (Fig. 4.5B). These findings point to an involvement of 







































Figure 4.5: VEGF induced O2- production is dependent on PI3K-Rac1 activation in 
Flk-1+ cells. (A), O2- generation of sorted Flk-1 positive cells isolated from 4-day-old em-
bryoid bodies in response to VEGF stimulation was analysed by determination of DHE fluo-
rescence. Cells depleted for p110  or NOX1 or wild type (pLKO.1) cells pre-treated for 30 
min with Rac1 inhibitor (50 M) were used. The graph shows percentage values (+/- stan-
dard deviation) *P < 0.05, statistically significant as indicated, n. s. not significant. Down 
regulation of NOX2 in Flk-1+ cells inhibits O2- production upon VEGF treatment. (B), O2- 
generation of sorted Flk-1 positive cells depleted for NOX1 or NOX2 or wild type (pLKO.1) 
cells isolated from 4-day-old embryoid bodies in response to VEGF stimulation was ana-
lysed by determination of DHE fluorescence. The graph shows percentage values in relation 
to VEGF treated cells (+/- standard deviation) *P < 0.05, statistically significant as indicated, 
n. s. not significant. 
 
4.6 PI3K catalytic subunit p110  is essential for vasculogenesis/angiogenesis  
It is known that VEGF, and more precisely VEGF A, is a central regulator of blood 
vessel formation (Neufeld et al. 1999). Moreover, we previously showed that vascu-
lar differentiation starts at day 4 of embryoid bodies culture (Bartsch et al. 2011). To 
investigate whether class IA PI3K , NOX1 and Rac1 are essential for VEGF signal-
ing pathways leading to vascular differentiation of the ES cells, p110  and NOX1 
shRNA embryoid bodies were treated from day 4 to day 10 of cell culture with 
VEGF (500 pM). This treatment resulted in a significant increase in vascular differ-
entiation in a non-targeting shRNA control (pLKO.1) as evaluated by quantification 
of endothelial marker PECAM-1 positive areas and branching points (Fig. 4.6A-C) 
as well as FCM (Fig. 4.6D,E) analysis for the percentage of Flk-1+ cells in embryoid 
bodies. In contrast, stimulation of vascular differentiation upon treatment with VEGF 
was nearly absent in embryoid bodies co-incubated with the general PI3K inhibitor 
wortmannin (1μM) and embryoid bodies lacking p110  catalytic subunits (see Fig. 
4.6A-C). Moreover, incubation the embryoid bodies with Rac1 inhibitor significantly  

































reduced the size of PECAM-1 positive vascular areas and nearly abolished the 
branching points (Fig. 4.6A-C) as well as the number of Flk-1+ cells (Fig. 4.6D,E). It 
was apparent that silencing the p110  catalytic subunit of PI3K resulted in signifi-
cant inhibition of the PECAM-1 positive vascular area and branching points (Fig. 
4.6A-C). In the absence of NOX1 or pharmacological inhibition of Rac1 a significant 
reduction of the VEGF-induced PECAM-1 positive vascular area and branching 
points in the embryoid bodies compared to untreated controls was observed,  al-
though still a significant enhancement of vascular differentiation occurred upon 
VEGF treatment (Fig. 4.6A-C). Taken together these experiments demonstrate that 
the PI3K catalytic subunit p110  as well as Rac1 and NOX1 regulate vascular dif-
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Figure 4.6: Class IA PI3K  and Rac1 are essential for VEGF-induced vascular differ-
entiation of ES cells. p110  or NOX1 knockdown and wild type (pLKO.1)ES cells were 
differentiated for 10 days. Inhibitors were applied from day 4 to day 10 of cell culture were 
stimulated with VEGF (500 pM) or left unstimulated. Cells were treated with wortmannin (1 
μM) or Rac1 inhibitor (50 M) as indicated. (A), representative immunefluorescence (IF) 
images showing the on vascular differentiation in embryoid bodies. The bars represent 100 
μm. (B,C), vascular differentiation as indicated by PECAM-1 positive areas (B) and branch-
ing points (C). (D,E), FCM analysis of Flk-1 expression in cells of embryoid bodies as well 
as after application of inhibitors from day 4 to day 10 of cell culture either in the absence or 
presence of VEGF (500 pM). *P < 0.05, statistically significant as indicated, n. s. not signifi-
cant. 
 
4.7 The catalytic subunit p110  is essential for angiogenesis 
Based on our previous studies, we believe that vasculogenesis starts around day 4 
and angiogenesis around day 6 during the differentiation of ES cells (Bartsch et al. 
2011). To examine the effect of pan-PI3K inhibition and specific PI3K subunit inhi-
bition targeting class 1A p110  catalytic subunits on angiogenesis, 6-day-old embry-
oid bodies were incubated with the inhibitors from day 6 to day 10 of cell culture. IF  
staining showed that incubation of embryoid bodies during the second phase of vas-
cular development with either wortmannin (1μM), a pan-inhibitor of PI3K members, 
or compound 15e (0.5 μM), a specific p110  inhibitor, significantly reduced the PE-
CAM-1positive vascular area and branching points (see Fig. 4.7A-C). Furthermore, 
2-APT (0.5 μM) an inhibitor of NOX1, significantly decreased the vascular area and 
branching points of PECAM-1 positive cells compared to the VEGF treated control, 
although VEGF still significantly increased the vascular area and branching points 
under these experimental conditions (Fig. 4.7A-C). Since Rac1 is required for NOX 
activation additional experiments were performed by blocking Rac1 activity using 




branching of endothelial cells and reduced the PECAM-1positive area compared to 
their respective control (Fig. 4.7A-C). However, VEGF treatment still significantly 
increased the CD31 positive area in the embryoid bodies co-incubated with Rac1 
inhibitor compared to untreated embryoid bodies, although to a lesser extent as com-
pared to the untreated control (Fig. 4.7A-C). 
 
Figure 4.7: Effects of pan-PI3K inhibitor and specific inhibitor of p110 , NOX1 and 
Rac1 on angiogenesis. ES cells were differentiated for 10 days. Inhibitors were applied from 
day 6 to day 10 of cell culture were stimulated with VEGF (500 pM) as indicated. Com-
pound 15e (0.5 μM) as well as the NOX1 inhibitor 2-acetylphenothiazine (2-APT, 0,5 μM), 
Rac1 inhibitor or left unstimulated. (A), representative IF images regarding vascular differ-
entiation of embryoid bodies. The bars represent 100 m. PECAM-1 positive areas (B) and 
branching points (C) *P < 0.05, statistically significant as indicated, n. s. not significant. 
 
4.8 Vascular progenitor cells isolated from shRNA p110  and shRNA NOX1 
embryoid bodies 
As previously described VEGF acts mainly on Flk-1, which serves as an early vascu-
lar marker (Choi et al. 1998, Kabrun et al. 1997). To guarantee a specific and signifi-
cant inhibition of the NOX1 isoform and the class IA PI3K catalytic subunit p110 , 
we screened the presence of mRNA and protein of NOX1 and p110  by RT-PCR 
and western blot in Flk-1+ cells isolated from knockdown embryoid bodies. As 
shown in Figure 4.8, PI3K catalytic subunit p110  was decreased in Flk-1+ isolated 
from shRNA p110  embryoid bodies within the time window of vascular differentia-




4.8A,B). Vice versa NOX1 mRNA production in Flk-1+ cells isolated from 4-day-old 
shRNA NOX1 embryoid bodies  was significantly decreased than compared pLKO.1 
cells, whereas no change was noticed in level of p110  cells (Fig. 4.8A,B). These 
data indicate that NOX1 production is not affected by down regulation of p110  and 
p110  not by down regulation of NOX1 (Fig. 4.8A,B). 
 
Figure 4.8: Level of p110  and NOX1 in Flk-1+ cells isolated from knockdown embry-
oid bodies. Flk-1 positive cells were MACS sorted from 4-day-old wild type (pLKO.1), 
shRNA p110  or shRNA NOX1 embryoid bodies. (A), mRNA from Flk-1 positive cells was 
prepared and expression level of p110 , NOX1 or Polymerase II was detected using RT-
PCR. Amplification was processed by DNA agarose gel electrophoresis. Representative gels 
for at least 3 repeated experiments are demonstrated. Graph beside the blot shows expression 
of p110  in relation to Polymerase II. (B), western blot analysis of p110  and NOX1. 
GAPDH was used as an internal standard. The blots shown are representative for at least 3 
experiments with consistent results. Graphs under the blots shows mean values (+/- standard 
deviation). *P < 0.05, statistically significant as indicated, n. s. not significant. 
 
4.9 p110  is essential for the formation of tube structures  
To further examine key factors regulating the sprouting of vascular structures, we 
investigated tube-like structure formation of Flk-1+ cells on matrigel, which recapitu-
lates the process of sprouting and tube formation that occurs during angiogenesis. 
Flk-1+ cells were plated on matrigel coated 96 multiwell plates. Images were taken 
after 16 h. The results showed that VEGF treatment significantly increased organiza-
tion of Flk-1+ cells into interconnected tubes and enhanced the formation of tube-like 
structures on matrigel (Fig. 4.9A). In contrast, pharmacologic inhibition of PI3K by 
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wortmannin completely inhibited VEGF-induced tube formation on matrigel. Quanti-
tative analysis showed that both the total length of tubes and number of branching 
points were clearly decreased after knockdown of p110  and NOX1 (Fig. 4.9B,C).  
Furthermore, shRNA p110  cells failed to form interconnected tubes even when 
stimulated with VEGF (Fig. 4.9A-C). Moreover, VEGF loses the ability to increase 
tube length and branching points in shRNA NOX1 Flk-1+ cells cultured on matrigel 
(Fig. 4.9A-C). Hence, our findings suggest that p110  as well as NOX1 are directly 
linked to VEGF-induced tube formation involved in the angiogenesis process. 
 
Figure 4.9: Angiogenesis assay for Flk-1+ cells after depleted p110  or NOX1. Flk-1+ 
cells were seeded on matrigel in 96-well plates. Tube structure was analyzed either in the 
presence or absence of VEGF (500 pM) after 16 h of cultivation. The ability to form tubes 
was expressed as total length of tubes and branching points per field. The bars represent 500 
m. (A), representative transmission images of tube formation of Flk-1+ cells on matrigel 
upon treatment with wortmannin (1 μM) or knock down of p110  or NOX1 in the presence 
or absence of VEGF (500 pM). (B,C), VEGF-induced capillary-like tube formation and 
branching points are significant inhibited in the presence of the nonspecific PI3K inhibitor 
wortmannin or silencing p110  and NOX1 in Flk-1+ cells. *P < 0.05, statistically significant 
as indicated, n. s. not significant. 
 
4.10 p110  and Rac1 are essential for Flk-1+ cell migration stimulated by VEGF  
To address the effect of VEGF on cell migration which is an essential step for the 
angiogenesis process a scratch migration assay was performed. In this experiment 
cell migration into the scratch area was assessed, 6 h after stimulation of plated Flk-
1+ cells with VEGF (500 pM). Analysis results showed that VEGF treatment signifi-




in VEGF-induced migration, we treated the Flk-1+ cells with wortmannin which to-
tally inhibited the migration of Flk-1+ cells (Fig. 4.10A,B). To determine whether 
silencing p110  or NOX1 could affect cell migration and hence the ability of the cell 
to form interconnected network structures, cells depleted for p110  or NOX1 were 
used in a scratch assay. A complete inhibition in migration of the p110  deficient 
Flk-1+ cells was observed (Fig. 4.10A,B). Furthermore, knocking down NOX1 in 
Flk-1+ cells caused a significantly reduction in cell migration and decrease in scratch 
closure compared to the VEGF treated pLKO.1 control (Fig. 4.10A,B). These data 
demonstrate that p110  is responsible for triggering cell migration stimulated by 
VEGF and may involve ROS generation by NOX1. 
 
Figure 4.10: VEGF positively regulates cell migration via PI3K signaling . (A), 
representative images of Flk-1+ cells isolated from 4-day-old embryoid bodies in the scratch 
assay for Flk-1+ wild type (pLKO.1), p110  or NOX1 shRNA cells, either alone or in the 
presence of VEGF (500 pM). The bars represent 200 m. (B), VEGF treated cells exhibited a 
highly induced migratory potential which was totally abolished by treatment of Flk-1+ cells 
with wortmannin or knocking down the catalytic subunit p110 . *P < 0.05, statistically sig-
nificant as indicated, n. s. not significant.  
 
4.11 VEGF induces cytoskeletal changes via p110  to induce Flk-1+ cell  
migration  
Actin cytoskeleton reorganization is a fundamental process in the regulation of cell 




this process we examined VEGF-induced actin cytoskeleton changes in Flk-1+ cells. 
As shown in representative micrographs of phalloidin-stained Flk-1+ cells, VEGF 
treated cells showed significant increase in lamellipodia structures and polarized cell 
shapes (Fig. 4.11A,B). Wortmannin treatment or knockdown p110  abrogated 
VEGF-induced lamellipodia structure and polarized shapes formation compared to 
the con trol group. In shRNA NOX1 cells still a significantly polarization after 
VEGF treatment compared with untreated cells was observed, although this effect 
























Figure 4.11: VEGF-induced changes in the Flk-1+ cell cytoskeleton reorganization de-
pending on PI3K. (A), representative images of Flk-1+ cells stained with phalloidin (green) 
and DAPI (blue). The bar represents 100 μm (upper) and 50 μm (lower). Lamellipodia (indi-
cated by arrow) were observed at the leading edge of VEGF-induced migrating cells. (B), 
VEGF induces actin cytoskeleton reorganization and showed significant increase in polar-
ized shapes of VEGF-induced Flk-1+ cells. Cell polarization was measured by formation the 
lamellipodium in the direction of migration. Wortmannin treatment and silencing p110  
abrogated VEGF-induced lamellipodia formation and polarized shapes of Flk-1+ cells. *P < 

























4.12 VEGF induces Rac1 and RhoA activity in the ES cells 
The primary requirement for lamellipodia formation is the activation Rac1 after ex-
tracellular stimuli (Disanza et al. 2005). In order to investigate the role of Rac1 in 
lamellipodia formation during cell migration, we performed western blot-based Rac1 
phosphorylation assay  from 5 day-old plated embryoid bodies stimulated with 
VEGF (500 pM). The results showed that the phosphorylation of Rac1 increased 
rapidly within 10 min after adding VEGF. Subsequently Rac1 activation decreased 
after 30 min but remained on a significantly elevated plateau as compared to 0 min 
(Fig. 4.12A).  Moreover, there was significant change in RhoA activation from 30 
min to 2 h after addition of VEGF (Fig. 4.12A). However, when the shRNA p110  
embryoid bodies were stimulated with VEGF, Rac1 (Fig. 4.12B) and RhoA (Fig. 
4.12C) activation was absent. In contrast, Rac1 (Fig. 4.12B) and RhoA (Fig. 4.12C) 
activation induced by VEGF was significantly increased in shRNA NOX1 embryoid 
bodies compared to the untreated control group. Pre-treatment of the shRNA NOX1 
embryoid bodies with compound 15e (0.5 μM), completely inhibited the increase of 
Rac1 (Fig. 4.12D) and RhoA (Fig. 4.12E) activation induced by VEGF. Collectively, 
these results suggest that VEGF-induced activation of Rac1 and RhoA in the ES cells 











Figure 4.12: VEGF-mediated activation of RhoA and Rac1 in ES cells depends on 
PI3K . ES cells were stimulated with VEGF (500 pM). Whole cell lysates were blotted and 
subjected to immunoblotting. Activation of Rac1 (Ser71) and RhoA was analyzed using 
phospho-specific antibodies. Blots were subsequently reprobed with pan-specific antibodies 




phospho-specific to pan-specific signals. The blots shown are representative for at least 3 
experiments with consistent results. Graphs under the blots shows mean values (+/- standard 
deviation) of 3 independent experiments. (A), kinetics of Rac1 and RhoA activation. Cells 
were subjected to immunoblotting at indicated time points after stimulation with VEGF. (B-
E), ES cells stably producing shRNA targeting p110 , NOX1 or pLKO.1 shRNA control 
were stimulated with VEGF and pre-treated for 30 min with compound 15e (0.5 μM) as in-
dicated. (D,E) *P < 0.05, statistically significant, n. s. not significant. 
 
4.13 VEGF stimulates Akt activation dependent on p110  and independent of 
NOX1 
Accumulating evidence has indicated that the PI3K-Akt pathway can be activated by 
growth factor and angiogenic stimuli  such as VEGF and angiopoietins (Jiang and 
Liu 2009). We first investigated whether VEGF could regulate Akt activation in 5-
day-old differentiating embryoid bodies. Our assays revealed that VEGF-induced 
Akt activation with an early peak at 10 min, which then returned to the basal levels 
after 30 min, while second peak of Akt activation appeared at 60 min (Fig. 4.13A). 
To determine whether VEGF-induced Akt activation is p110  dependent, we 
blocked p110  by compound 15e inhibitor, and examined Akt activation upon VEGF 
treatment. We found that pre-treatment the cells with 0.5 μM compound 15e totally 
abolished the effect of VEGF on Akt activation (Fig. 4.13B). To check whether 
NOX1 is involved in VEGF-induced Akt activation, we blocked NOX1 activity by 
using 2-APT and examined Akt activity after VEGF treatment (Fig. 4.13C). Interest-
ingly, our results showed that pre-treatment with 0.5 μM 2-APT did not affect 
VEGF-induced Akt activity. To verify the results obtained from the specific inhibitor 
we used ES cells depleted p110  or NOX1. As expected, down regulation of p110  
resulted in significant inhibition in Akt phosphorylation upon VEGF treatment (Fig. 
4.13D). In contrast, non-significant decrease in Akt phosphorylation was observed 
after suppression of NOX1 (Fig. 4.13D). The second peak of Akt activity was also 
inhibited by 10 nM BIM-1 (PKC inhibitor) (Fig. 4.13E). Thus our data indicate a 
crosslink between PI3K and PKC pathway during VEGF-induced vasculogenesis in 
ES cell derived embryoid bodies. Taken together these results suggest that p110  but 
















Figure 4.13: Activation of Akt by VEGF is dependent on class 1A PI3K  but not 
NOX1. Whole cell lysates were blotted and subjected to immunoblotting. Activation of Akt 
(Ser473) was analyzed using phospho-specific antibodies. Blots were subsequently reprobed 
with specific antibodies recognizing Akt. Specific activation was quantified as ratio of phos-
pho-specific to specific signals. The blots shown are representative for at least 3 experiments 
with consistent results. Graphs under the blots shows mean values (+/- standard deviation) of 
3 independent experiments. (A), time course of Akt and phospho-Akt (Ser473) upon VEGF 
treatment. Note that VEGF stimulated Akt phosphorylation after 10 min. (B-D), after 30 min 
pre-treatment with inhibitor and VEGF for the indicated time, the level of total Akt and 
phospho-Akt (Ser473) in embryoid bodies was determined. (B), compound 15e (0.5 μM) 
inhibited the upregulation of phospho-Akt (Ser473) induced by VEGF (500 pM). (C), the 
NOX1 inhibitor 2-APT did not affect VEGF-induced Rac1 activity. (D), knock down of 
p110  resulted in significant inhibition in Akt phosphorylation upon VEGF treatment. In 
contrast, non-significant decrease in Akt phosphorylation was observed after silencing 
NOX1. (E), second peak of Akt activation at 60 min after VEGF treatment was blunted by 
pre-treatment with 10 nM BIM-1 (PKC inhibitor). *P < 0.05, statistically significant as indi-
cated, n. s. not significant. 
 
4.14 Targeting p110  catalytic subunit inhibits VEGF-induced MAP kinase 
p44/42 activation 
MAP kinase activation was measured using phosphor-specific antibodies to elucidate 
the signaling pathway involved in response to VEGF stimulation. After incubation 
with VEGF (500 pM) we could observe a high level of MAP kinase phosphor-p44/42 




PI3K inhibitor wortmannin completely prevented this activation (Fig. 4.14). More-
over, MAP kinase p44/42 activation upon VEGF treatment was absent in the pres-
ence of the p110  catalytic subunit inhibitor compound 15e (Fig. 4.14). In contrast, 
the NOX1 inhibitor (2-APT) did not affect p44/42 activation after VEGF treatment 
(Fig. 4.14). Furthermore, no significant involvement of JNK or p38 MAP kinase 
pathway could be observed in response to VEGF stimulation (Fig. 4.14). Thus our 




Figure 4.14: Targeting p110  catalytic subunit inhibits VEGF-induced MAP kinase 
p44/42 activation. Whole cell lysates were blotted and subjected to immunoblotting. Activa-
tion of protein was analyzed using phospho-specific antibodies. Blots were subsequently 
reprobed with specific antibodies recognizing total protein. Specific activation was quanti-
- - - - - -
- - - - + +
- - + + - -







































fied as ratio of phospho-specific to specific signals. The blots shown are representative for at 
least 3 experiments with consistent results. Graphs under the blots shows mean values (+/- 
standard deviation) of 3 independent experiments. MAP kinase p44/42 phosphorylation by 
VEGF is blocked by wortmannin and compound 15e in 5-day-old embryoid bodies. In con-
trast inhibition of NOX1 by 2-APT did not impair the activation of p44/42 observed upon 
VEGF treatment. No significant involvement of JNK or p38 MAPK pathway could be ob-
served in response to VEGF stimulation. *P < 0.05, statistically significant as indicated, n. s. 
not significant. 
 
4.15 Silencing the p110  inhibits tumor-induced angiogenesis in confrontation 
cultures of embryoid bodies and multicellular prostate cancer spheroids
Tumor vascularization of DU-145 prostate tumor spheroids was investigated in con-
frontation cultures with vascularized embryoid bodies to analyse further the role of 
PI3K and p110  as anti-angiogenic target. In the presents experiment we investigated 
the effects of wortmannin (1μM) on tumor-induced angiogenesis using co-culturing 
of embryonic stem cell-derived embryoid bodies and multicellular tumour spheroids, 
which were previously established by Wartenberg et al. (Wartenberg et al. 2001) as 
in vitro system to study tumor-angiogenesis. We found that wortmannin (1μM) 
strongly reduced the percentage of vascularized tumor (6.6 ± 5.5%) and the vascu-
larization of multicellular tumor spheroids in confrontation cultures in comparison 
with untreated control (Fig. 4.15A-D). interestingly, silencing the p110  catalytic 
subunit of PI3K resulted in significantly reduced the tumor vascularisation and the 
percentage of vascularized tumor spheroids (20 ± 10%) as compared to the pLKO.1 
control (Fig. 4.15A,B). Furthermore, the positive area in vascularized tumor sphe-
roids was significantly abolished in the absence of p110  (Fig. 4.15E,F), which 
clearly underscores the meaning of this isoform as an anti-angiogenic target. More-
over, silencing the NOX1 significantly reduced the tumor vascularisation and the 
percentage of vascularized tumor spheroids (72,6 ± 8,2%) as compared to the 
pLKO.1 control (Fig. 4.15G,H). However, tumor vascularisation and the percentage 
of vascularized tumor spheroids in silencing the NOX1 still highly significant in 
compared with silencing the p110  catalytic subunit of PI3K. In contrast, confronta-
tion cultures incubated with 1μM Rac1 inhibitor from day 6 to day 8 totally inhibited 
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Figure 4.15: Inhibition of tumor-induced angiogenesis by silencing the p110 . The endo-
thelial cells were visualized by anti-PECAM-1 (CD31, red color). The tissue of multicellular 
DU-145 prostate tumor spheroids was visualized by long-term cell tracker dye 5-
chloromethylfluorescein diacetate (CMFDA) (green color). The bars represent 500 μm. His-
tograms of PECAM-1fluorescence (solid red line) and CMFDA fluorescence (dotted green 
line) are presented as fluorescence counts in relation to the distance from the embryoid body 
periphery. (A,B), representative immunefluorescence (IF) images showing the tumor-
induced angiogenesis in confrontation cultures consisting of embryoid bodies pLKO.1 con-
trol and multicellular DU-145 prostate tumor spheroids. (C,D), confrontation cultures incu-
bated with 1μM wortmannin from day 6 to day 8. (E,F), confrontation cultures with embry-
oid bodies stably producing shRNA targeting p110  catalytic subunit. (G.H), confrontation 
cultures with embryoid bodies stably producing shRNA targeting NOX1, (I,J) confrontation 
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It has been established that VEGF signaling is crucial for both normal and disease-
associated vascular development (Ferrara 2009). In fact, the mechanism of the VEGF 
stimulation on blood vessels formation has been the subject of intensive research 
over the last two decades (Connolly et al. 1989, Ferrara and Henzel 1989, Keck et al. 
1989, Leung et al. 1989). There are a number of studies describing that VEGF could 
activate PI3K and stimulate vascular differentiation (Bekhite et al. 2011, Gerber et al. 
1998, Jiang and Liu 2009). Moreover, inhibition PI3K activity by wortmannin or 
LY294002, which are first generation PI3K inhibitors, decreased VEGF-induced 
endothelial cell survival (Gerber et al. 1998). However, targeting vascular develop-
ment by using wortmannin additionally inhibits PI3K-related kinases such as mTOR 
and PI4-kinase ß (Finan and Thomas 2004). Furthermore, these inhibitors do not 
discriminate between different PI3K isoforms, which are important for all organ sys-
tems (Marone et al. 2008). To overcome these disadvantages, many inhibitors target-
ing specific PI3K catalytic subunit were developed (Marone et al. 2008). 
There is strong evidence in the literature to indicate that Akt is a major downstream 
target of PI3K for regulating angiogenesis. (Jiang and Liu 2009, Morello et al. 2009). 
However, selective involvement of specific class IA PI3K in vascular signalling 
pathways is not known (Cebe-Suarez et al. 2006, Gliki et al. 2002, Laramee et al. 
2007). In addition, the contribution of VEGF to activate ROS production through 
PI3K and its involvement in vascular differentiation is still not fully understood 
(Chatterjee et al. 2012, Chen et al. 2006, Kennedy and DeLeo 2008). It has been pre-
viously demonstrated that the family of NADPH oxidases (NOX) plays an important 
role in ROS production in response to VEGF in non-phagocytic cells such as endo-
thelial cells (Ushio-Fukai et al. 2002, Yamaoka-Tojo et al. 2004). 
Embryonic stem (ES)   cells are pluripotent cells derived from the early mouse em-
bryo that can be propagated stably in the undifferentiated state in vitro. ES cells are 
maintained in vitro as totipotent stem cells by culture on a feeder layer of embryonic 
fibroblasts or in the presence of the cytokine leukemia inhibitory factor (LIF). When 
LIF is removed, they are able to spontaneously undergo in vitro differentiation, either 
in monolayer or form embryo-like aggregates, called embryoid bodies, into all the 
derivatives of the inner cell mass cells (ICM). The embryoid bodies can also give rise 
to highly differentiated cells when embryoid bodies formed in suspension are subse-




strated that ES cells differentiate in vitro to endothelial cells through successive mat-
uration steps with sequential expression of cell lineage-specific markers: platelet 
endothelial cell adhesion molecule (PECAM,CD31), VEGF receptors, VEGFR1 
(fms-related tyrosine kinase-1, Flt-1) and VEGFR2 (fetal liver kinase-1 Flk-1/KDR), 
tyrosine kinase with immunoglobulin-like and EGF-like domains 1 (tie-1), tie-2 and 
vascular endothelial cadherin (VE-cadherin), (Kabrun et al. 1997, Redick and Bautch 
1999).  
In this study, we for the first time studied the time course of class IA PI3K catalytic 
subunits p110 , Flk-1 and PECAM-production as well as intracellular ROS produc-
tion in embryoid bodies. Our results indicated a striking synchronicity in the occur-
rence of endothelial cell markers with the appearance of class IA PI3K catalytic sub-
units p110  and ROS generation. Thus it was reasonable to speculate that p110  and 
ROS may be playing a role during the vascular differentiation. Moreover, Flk-1+ 
cells isolated from 4-day-old embryoid bodies mainly produced NOX1 and NOX4. 
Furthermore, class IA PI3K catalytic subunit p110  was produced in Flk-1+ cells, 
suggesting its involvement in vascular differentiation. This assumption is supported 
by studies showing that knock out of  p110  in endothelial cells results in embryonic 
lethality at mid-gestation with defective development of the major vessels and lack 
of small branched vessels (Graupera et al. 2008). 
The importance of NOX in ROS production was linked with PI3K pathway by sev-
eral authors (Nakanishi et al. 2014, Seshiah et al. 2002, Xu et al. 2011), however, the 
precise signaling mechanisms of VEGF on NOX stimulation through PI3K are not 
yet completely understood (Chatterjee et al. 2012, Cheng et al. 2006, Kennedy and 
DeLeo 2008, Ushio-Fukai 2006). To elucidate a potential crosslink between PI3K 
and NADPH oxidase activation embryoid bodies were incubated during the time of 
VEGF treatment with PI3K inhibitors. This treatment significantly decreased ROS 
production in embryoid bodies. Moreover, we showed that VEGF stimulation of in-
tracellular ROS formation was completely inhibited by the NADPH oxidase inhibi-
tors DPI, VAS2870 and apocynin but not by rotenone. Previous data have shown that 
apocynin is able to prevent p47phox and p47phox homolog translocation to the plasma 
membrane, thereby inhibiting the NADPH oxidases to be active and functional 
(Banfi et al. 2003, Touyz et al. 2002). ROS formed by VEGF stimulation in might be 
derived from NOX1 and NOX2 (Bedard and Krause 2007). To further test the role of 




the shRNA p110  and shRNA NOX1 embryoid bodies with VEGF and observed that 
VEGF failed to increase the ROS level. In contrast, treatment of shRNA NOX2 em-
bryoid bodies with VEGF did not affect the ROS production, indicating that NOX2 
is not involved in ROS production during. These data were confirmed in Flk-1+ cells 
where VEGF treatment strongly elevated O2- generation which was significantly in-
hibited by wortmannin.  Furthermore, knockdown p110  or NOX1 in Flk-1+ cells 
abolished the effects of VEGF on O2- production. In contrast, knockdown of NOX2 
in the Flk-1+ cells did not show significant effects on O2- production. It is well 
known that the GTPase Rac1 plays a critical role in VEGF-induced O2- formation via 
NADPH oxidase activation in different cell types (Abid et al. 2001, Ushio-Fukai et 
al. 2002). Therefore, we investigated the role of Rac1 in O2- generation of differenti-
ating ES cells. As expected Rac1 inhibitor abolished the VEGF mediated increase in 
O2- production, thus pointing to an involvement of Rac1 in VEGF-induced O2- pro-
duction through activation of NOX1. This result is consistent with a previous report 
which suggested a direct link between Rac1 activity and ROS production in non-
phagocytic cells (Sundaresan et al. 1996).  
It is generally accepted that the PI3K pathway is important in mediating VEGF stim-
ulation of endothelial cell proliferation, migration and tube formation (Gingras et al. 
2000, van Nieuw Amerongen et al. 2003, Yuan et al. 2008). However, the precise 
signaling mechanism of VEGF-PI3K in vascular development is not yet completely 
understood. In this study, we have shown that treatment the embryoid with VEGF 
resulted in a significant increase in vascular differentiation in the pLKO.1 ES cells. 
This effect was still obvious in NOX1 depleted embryoid bodies but to a signifi-
cantly lesser degree. Treatment of embryoid bodies with PI3K inhibitors reduced not 
only the area of PECAM-1 positive cells but also the vessel-like structures in embry-
oid bodies. These results are consistent with the previously demonstrated link be-
tween PI3K and vascular differentiation (Hamada et al. 2005, Jiang et al. 2000). 
PI3K probably stimulates vascular differentiation through one or several isoforms 
(Yuan et al. 2008). Thus, we targeted single isoforms to avoid side effects of pan-
PI3K inhibitor on the immune system, which is largely dependent on p110  and 
p110  (Banham-Hall et al. 2012). Our results demonstrated that the increase in the 
vascular differentiation upon treatment with VEGF was nearly absent in the presence 
of p110  inhibitor or silencing p110  subunits. Similar findings were observed in 




embryonic lethality at mid-gestation due to severe defects in angiogenic sprouting 
and vascular remodelling (Graupera et al. 2008). Furthermore, Rac1 inhibitor signifi-
cantly reduced the size of PECAM-1 positive area and nearly abolished branching 
points in embryoid bodies. These results are consistent with data from other groups  
which demonstrated that PI3K and Rac1 are required for vascular function (Fiedler 
2009, Soga et al. 2001) as well as for VEGF-dependent angiogenesis in endothelial 
cells (Colavitti et al. 2002, Zhang et al. 2012). In addition, an essential role for Rac1 
in mediating the effect of VEGF on endothelial cell proliferation and migration in 
vitro and in inducing angiogenesis in a mouse sponge implant model has been re-
ported (Ushio-Fukai et al. 2002).  
In the present study, using shRNA knockdown embryoid bodies enabled us to exam-
ine the contribution of p110  and NOX1 in the vascular development. Previous re-
ports have shown that the most relevant NOX isoforms in vascular cells are pre-
sumably NOX1 and NOX2, which can both be regulated through Rac1 (Chatterjee et 
al. 2012). Our results showed that NOX1 is produced at significant higher levels 
compared to NOX2, which was scarcely present in Flk-1+ cells. Results from tube-
like structure formation and scratch migration assay using Flk-1+ cells indicted that 
shRNA p110  Flk-1+ cells failed to migrate and to form interconnected tubes even 
when stimulated with VEGF. Likewise, silencing NOX1 in Flk-1+ cells caused a 
significantly reduction in cell migration and tubes length as well as the branching 
points upon VEGF treatment. Hence, our findings suggest that p110  as well as 
NOX1 are important for VEGF-induced tube formation. Since VEGF still increased 
the number of Flk-1+ cells  in NOX1 shRNA embryoid bodies it may be concluded 
that  NOX1 is not required for the initial stages of vasculogenesis but is playing a 
role in the migration and sprouting of the endothelial cells to promote the establish-
ment of capillary-like networks upon VEGF treatment. It may be further speculated 
that other NOX isoforms, e.g. NOX4 may overtake the function of NOX1 in NOX1 
shRNA embryoid bodies. Consistent with our data others have suggested a role for 
Nox1 in stimulating branching morphogenesis of sinusoidal endothelial cells 
(Kobayashi et al. 2004). Moreover it has been shown that mice deficient in NOX1, 
but not NOX2 or NOX4, exhibit significant reduction in angiogenesis (Garrido-
Urbani et al. 2011).  
It is well known that  remodelling of the actin cytoskeleton is essential for cell migra-




Flk-1+ cells displayed polarized shapes due to formation of lamellipodia during cell 
migration. Pre-treatment with wortmannin or silencing p110  in Flk-1+ cells abro-
gated VEGF-induced lamellipodia structure formation. Moreover the absence of 
NOX1 in Flk-1+ cells resulted in significant inhibition in polarized cell numbers, 
although this effect was less pronounced as compared to conditions of PI3K inhibi-
tion. These observations may suggest that class IA PI3K  signaling is required for 
cytoskeletal changes during cell migration, whereas, silencing NOX1 in Flk-1+ cells 
is affecting lamellipodia structure formation. Cell migration is a fundamental aspect 
of cancer cell growth (Jimenez et al. 2000) and is a complex process that requires the 
high coordination of actin polymerization, formation, release of focal adhesions and 
myosin motor activity (Lauffenburger and Horwitz 1996). An important finding in 
this study is that the inhibition of p110  by shRNA significantly decreased the rate of 
cell migration. This demonstrates that the p110  subunit affects multiple cell func-
tions and also reveals the expected functions of the PI3K isoforms on cancer cells. 
Several lines of investigation have indicated that Rac1 plays a crucial role in trans-
ducing the signals from cell surface receptors to downstream effectors and is in-
volved in cell migration and gene expression (Burridge and Wennerberg 2004, 
Etienne-Manneville and Hall 2002). In addition, Rac1is involved in cytoskeleton 
organization and is defining cell shape and morphology (Colley 2000, Etienne-
Manneville and Hall 2002). A previous study has demonstrated that Rac1 is involved 
in the control of angiogenesis by inducing ROS production (Diebold et al. 2009, Li et 
al. 2010, Tobar et al. 2008). In our study, suppression of p110  using shRNA signifi-
cantly inhibited the activation of Rac1 and RhoA in ES cells upon VEGF treatment. 
This is in line with previous studies which showed that the activation of Rac1 is se-
lectively dependent on the p110  isoform of PI3K (Graupera et al. 2008). Since 
NOX1 was produced in the Flk-1+ cells and shRNA-mediated dwonregulation of 
NOX1 suppressed ROS generation, our findings are in line with the observation that 
VEGF stimulates ROS production via activation of Rac1-dependent NADPH oxidase 
(Ushio-Fukai 2007) or Rac1-regulated NOX1 enzyme (Cheng et al. 2006, Miyano et 
al. 2006). Collectively, these data suggest that PI3K functions as an upstream activa-
tor of Rac1 and RhoA and subsequently affects the cytoskeleton and induces endo-
thelial cell migration. Moreover, NOX1 may take part in VEGF-induced cell migra-




Akt is known to be involved in the regulation of angiogenesis (Fujio et al. 2000, 
Shiojima and Walsh 2006). Moreover, we and other groups provided direct evidence 
that the PI3K-Akt pathway is required for VEGF to induce vascular development 
(Abid et al. 2004, Bekhite et al. 2011, Karar and Maity 2011). In this study, we 
showed that VEGF induced Akt activation with an early peak at 10 min while asec-
ond peak of Akt activation appeared at 60 min. Given that the activation of Akt has 
been shown to play an essential role in VEGF-PI3K stimulation (Madeddu et al. 
2008), we thought that it was possible that NOX1 may regulate Akt in embryoid bod-
ies. However, our data demonstrated that inhibition of NOX1 did not impair VEGF-
induced Rac1 as well as Akt phosphorylation.  Therefore our results indicate that 
p110  but not NOX1 act as the upstream effector of Rac1 and Akt activation.  
In an effort to elucidate further the pathway by which MAP kinase VEGF stimulates 
the vascular differentiation.  MAP kinase activation was measured to elucidate 
whether the class IA PI3K  and NOX1 are essential for VEGF-MAP kinases signal-
ling pathways leading to vascular differentiation. As seen in the results, stimulation 
the embryoid bodies with VEGF showed a high level of phosphor-p44/42 in 5-day-
old embryoid bodies within 10 minutes. We also observed that MAP kinase p44/42 
phosphorylation was blocked by wortmannin the PI3K inhibitor and the p110  in-
hibitor compouned15e. While 2-APT the NOX1 inhibitor was not able to prevent the 
VEGF-induced MAP kinase p44/42 phosphorylation. Furthermore, no significant 
involvement of JNK or p38 MAP kinase pathway could be observed in response to 
VEGF stimulation. Based on currently evidence, PI3K as well as PI3K catalytic sub-
unit p110  are involved in VEGF mediated vascular differentiation processes. These 
findings indicated a regulatory role of the PI3K pathway through the activation of 
MAP kinase p44/42. Qiang et al. (Qiang et al. 2002) also reported this crosstalk be-
tween the PI3K and MAP kinase p42/44 in human myeloma cells. The phosphoryla-
tion status of the other MAP kinases e.g. p38 and JNK did not change after stimula-
tion embryoid bodies with VEGF, suggesting that effects of VEGF on vascular dif-
ferentiation of ES cells are mediated by MAP kinase p44/42. Our hypothesis is con-
sistent with previous findings demonstrating that activation of MAP kinase p44/42 is 
essential for cell differentiation induced by VEGF (Ferrara et al. 1996, Pimentel et al. 
2002).  
Similar to embryos, growing any tumor more than 2mm needs functional blood ves-




angiogenic switch (Leite de Oliveira et al. 2011). This will supply the tumor with 
oxygen. Experimental and clinical evidence suggests that the process of metastasis is 
also angiogenesis dependent. For a tumor cell to metastasize successfully, it must 
breach several barriers and respond to specific growth factors (Fidler et al. 1978, 
Nicolson 1988a, Nicolson 1988b). Thus, tumor cells must gain access to the vascula-
ture in the primary tumor, survive the circulation, arrest in the microvasculature of 
the target organ exit from this vasculature, grow in the target organ and induce an-
giogenesis (Weidner et al. 1991, Weinstat-Saslow and Steeg 1994, Zetter 1998). 
Therefore, angiogenesis appears to be necessary at the beginning as well as at the 
completion of the metastatic cascade. Hence, if it were possible to prevent tumors 
from being vascularized cancer could probably be cured (Folkman 1971). Antiangio-
genic therapy is currently one of the most promising and efficient therapies against 
cancer. This has initiated intensive research for novel antiangiogenic agents that ex-
ert specific effects on endothelial cell migration and/or proliferation as well as for 
innovative in vitro models to study the efficacy of antiangiogenic compounds 
(Sounni and Noel 2013).  
In addition to normal physiological angiogenesis, the ES derived embryoid bodies 
system used in confrontation cultures with multicellular tumor spheroids is also suit-
able for studying tumor-induced angiogenesis. Invasion of endothelial cells into the 
tumor tissue can be observed in tumor spheroids cultivated in confrontation cultures 
with embryoid bodies which became efficiently vascularised within a few days 
(Wartenberg et al. 2001). This angiogenesis resulted in the growth stimulation of the 
tumor spheroid, the disappearance of the central necrosis, the improvement of oxy-
gen supply and the downregulation of the expression of both HIF-1 and VEGF, fea-
tures normally observed during the vascularization of a tumor tissue (Wartenberg et 
al. 2001).  
To examine the role of PI3K/p110  and NOX1 pathway in tumor-induced angio-
genesis, we used confrontation culture consists of embryoied bodies derived from ES 
cells and multicellular tumor spheroids from human prostate carcinoma cell line 
(DU-145). Interestingly, we found PI3K inhibitor wortmannin and silencing p110  
can strongly inhibited the vascularization of multicellular tumor spheroids in con-
frontation cultures, NOX1 knockdown has no strong effect as p110  knockdown on 





5.1 Conclusion  
Taken together, our data demonstrated that the VEGF-VEGFR-PI3K-Akt/Rac1 sig-
naling pathway plays a vital role in VEGF-induced blood vessels differentiation. 
Further analysis of this signaling cascade demonstrates that p110  is critical for vas-
cular development because silence p110  causes defective vasculogenesis and an-
giogenesis, while VEGF-PI3K-NOX1 is involved in angiogenesis through O2- gen-
eration. Interestingly, silencing p110  can strongly inhibited the vascularization of 
multicellular tumor spheroids in confrontation cultures. Importantly, these findings 
provide direct evidence that the activity of p110  in endothelial cells is essential for 
vascular development and suggest that p110  and their downstream signalling cas-
cade may represent promising therapeutic targets for the treatment of numerous hu-
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